An overview of the key routes to the best selling 5-membered ring heterocyclic pharmaceuticals

  1. ,
  2. ,
  3. and
Innovative Technology Centre, Department of Chemistry, University of Cambridge, Lensfield Road, CB2 1EW Cambridge, UK
  1. Corresponding author email
Editor-in-Chief: J. Clayden
Beilstein J. Org. Chem. 2011, 7, 442–495.
Received 10 Dec 2010, Accepted 22 Mar 2011, Published 18 Apr 2011
cc by logo


This review presents a comprehensive overview on selected synthetic routes towards commercial drug compounds as published in both journal and patent literature. Owing to the vast number of potential structures, we have concentrated only on those drugs containing five-membered heterocycles and focused principally on the assembly of the heterocyclic core. In order to target the most representative chemical entities the examples discussed have been selected from the top 200 best selling drugs of recent years.


Over the past few decades organic chemistry has seen tremendous progress and this has enabled the synthetic chemist to assemble virtually any molecular structure imaginable given reasonable time and sufficient resources. A steady increase in architectural complexity and the incorporation of more diverse molecular functionality has been a notable feature of pharmaceutical research and development. This general trend has emerged as a consequence of the better understanding of the genome and has resulted in many highly specific therapeutic targets being elucidated.

However, even today it might be argued that because of the perceived simpler structures of drug molecules when compared to complex natural products, only a limited repertoire of synthetic transformations are utilised for their construction. Furthermore, many of the modern pioneering developments in organic synthesis including new highly selective and mild bond forming reactions such as metathesis and C–H activation, asymmetric transformations as well as polymer- and technology-assisted syntheses are underused.

In order to evaluate the validity of this hypothesis we decided to investigate the syntheses of the best-selling pharmaceutical substances focusing not only on the type of transformations involved but more importantly on the way the heterocyclic components were assembled. Aromatic and non-aromatic heterocyclic rings are a predominant architectural constant of pharmaceuticals and allow for variable interactions with the biological target which are not possible using simpler carbocyclic motifs. Based on our observations, we will moreover be able to evaluate the degree these privileged structures utilise innovative and challenging synthetic strategies. In addition, it will be possible to establish which reactions are most frequently employed and which ones are surprisingly rare or notably absent. Furthermore, from this study it will be possible to judge whether novel methods and transformations developed within the academic community are commonly applied in the later stages of drug research.

In order to illustrate the diversity of synthetic methods used by the pharmaceutical industry to generate heterocycle containing molecules we decided in the first part of this review to focus mainly on five-membered aromatic heterocycles represented within the top 200 best selling drugs [1,2]. This review abstracts information available from many literature sources including patents to provide a selection of the most commonly used routes in drug synthesis. Different heterocyclic structures will be introduced and discussed in individual subsections. In Table 1 a summary of these structures is shown. We believe that this article will give an enlightening overview of both the classical heterocycle syntheses as well as interesting but less used transformations.

Table 1: Heterocylic structures discussed in this review.

Name Label Structure Heterocycle core  
atorvastatin 1 [Graphic 1] pyrrole Figure 1
sunitinib 36 [Graphic 2] pyrrole Scheme 7
sumatriptan 49 [Graphic 3] indole Scheme 9
zolmitriptan 50 [Graphic 4] indole Scheme 9
naratriptan 69 [Graphic 5] indole Scheme 15
rizatriptan 76 [Graphic 6] indole Scheme 17
eletriptan 87 [Graphic 7] indole Scheme 20
fluvastatin 2 [Graphic 8] indole Scheme 25
ondansetron 119 [Graphic 9] indole Scheme 27
tadalafil 132 [Graphic 10] indole Scheme 28
carvedilol 136 [Graphic 11] carbazole Figure 4
etodolac 153 [Graphic 12] carbazole
Scheme 31
losartan 157 [Graphic 13] imidazole Figure 5
olmesartan 158 [Graphic 14] imidazole Scheme 36
ondansetron 119 [Graphic 15] imidazole Scheme 37
esomeprazole 190 [Graphic 16] benzimidazole Scheme 39
pantoprazole 193 [Graphic 17] benzimidazole Scheme 40
candesartan 204 [Graphic 18] benzimidazole Scheme 41
telmisartan 217 [Graphic 19] benzimidazole Scheme 43
zolpidem 227 [Graphic 20] imidazopyridine Scheme 45
celecoxib 235 [Graphic 21] pyrazole Figure 7
pazopanib 246 [Graphic 22] indazole Scheme 50
anastrozole 257 [Graphic 23] 1,2,4-triazole Scheme 51
rizatriptan 76 [Graphic 24] 1,2,4-triazole Scheme 51
letrozole 256 [Graphic 25] 1,2,4-triazole Scheme 51
sitagliptin 275 [Graphic 26] 1,2,4-triazole Scheme 55
maraviroc 286 [Graphic 27] 1,2,4-triazole Scheme 57
alprazolam 297 [Graphic 28] 1,2,4-triazole Scheme 58
itraconazole 307 [Graphic 29] 1,2,4-triazole Figure 9
rufinamide 315 [Graphic 30] 1,2,3-triazole Scheme 61
valsartan 319 [Graphic 31] tetrazole Scheme 62
losartan 157 [Graphic 32] tetrazole Scheme 63
cilostazole 325 [Graphic 33] tetrazole Scheme 64
cefdinir 329 [Graphic 34] thiazole Figure 11
ritonavir 337 [Graphic 35] thiazole Scheme 66
pramipexole 345 [Graphic 36] thiazole Scheme 67
famotidine 352 [Graphic 37] thiazole Scheme 69
febuxostat 359 [Graphic 38] thiazole Scheme 70
ziprasidone 367 [Graphic 39] thiazole Scheme 71
ranitidine 377 [Graphic 40] furan Scheme 73
nitrofurantoin 382 [Graphic 41] furan Scheme 74
amiodaron 385 [Graphic 42] furan Scheme 76
raloxifene 392 [Graphic 43] thiophene Scheme 77
olanzapine 399 [Graphic 44] thiophene Scheme 79
clopidogrel 420 [Graphic 45] thiophene Scheme 81
timolol 432 [Graphic 46] thiadiazole Figure 14
tizanidine 440 [Graphic 47] thiadiazole Scheme 85
leflunomide 446 [Graphic 48] isoxazole Scheme 86
sulfamethoxazole 447 [Graphic 49] isoxazole Scheme 87
risperidone 454 [Graphic 50] benzoisoxazole Scheme 88



Pyrrole, a five-membered nitrogen containing heterocycle is present in some of the most common biologically important molecules, i.e., chlorophyll and haem. However, while the pyrrole ring is not widely represented in pharmaceutical compounds, the core structure of atorvastatin (1, Lipitor; Figure 1), the best-selling drug substance of the last few years, does contain a penta-substituted pyrrole ring. This drug is an example of a competitive HMG-CoA-reductase inhibitor belonging to the 7-substituted 3,5-dihydroxyheptanoic acid family. In atorvastatin this important syn-1,3-diol moiety is connected to the other functional constituents through a fully substituted pyrrole ring instead of the more elaborate systems which are encountered in other members of this family.


Figure 1: Structures of atorvastatin and other commercial statins.

The initial synthesis of atorvastatin was reported by the Warner–Lambert company [3]. From structure–activity relationship (SAR) studies it was found that the addition of substituents at the 3- and 4-position of the pyrrole scaffold significantly increases potency when compared to the more classical 2,5-disubstituted pyrroles. This study culminated in the discovery of atorvastatin which has a five times greater potency then the initial lead, the fungal metabolite compactin (5, Figure 2).


Figure 2: Structure of compactin.

Although it was possible to construct such fully substituted pyrrole rings by ZnCl2-catalysed condensation reactions between a functionalised enamine 6 and simple benzoin (7), this method proved to be less successful for more complex pyrroles of which atorvastatin was an example (Scheme 1).


Scheme 1: Synthesis of pentasubstituted pyrroles.

In order to prepare the 5-isopropylpyrrole derivative 16 a more efficient [3 + 2] cycloaddition of an acetylene component with an amido acid 13 was developed. Unfortunately, reacting ethyl phenylpropiolate with the corresponding amido acid in hot acetic anhydride afforded a 4:1 mixture of regioisomers with the major product being the undesired regioisomer (Scheme 2).


Scheme 2: [3 + 2] Cycloaddition to prepare 5-isopropylpyrroles.

However, the analogous reaction with isomer 19 was found to be completely regiospecific leading to the formation of the desired product 16 albeit in only moderate yield (Scheme 3).


Scheme 3: Regiospecific [3 + 2] cycloaddition to prepare the pyrrole scaffold.

By modification of the coupling partners a more defined dipolar [3 + 2] cycloaddition between N,3-diphenylpropynamide (22) and an in situ generated mesoionic species 21 furnished the desired product 23 regiospecifically [4] (Scheme 4).


Scheme 4: Formation of the pyrrole core of atorvastatin via [3 + 2] cycloaddition.

A further synthetic approach was based on the classical Paal–Knorr cyclocondensation of a highly substituted 1,4-diketone with a primary amine bearing a masked aldehyde functionality. The 1,4-diketone component, which can be accessed via a 3-step sequence [5] starting from aniline, was refluxed with 3-aminopropionaldehyde diethylacetal 32 in toluene under mildly acidic conditions to afford the fully substituted pyrrole motif in 81% isolated yield following crystallisation [6]. The key transformation in this sequence is a thiazolium-mediated Stetter reaction between 4-fluorobenzaldehyde (29) and an advanced Michael acceptor obtained from an initial Knoevenagel condensation (Scheme 5).


Scheme 5: Formation of pyrrole 33 via the Paal–Knorr reaction.

In order to improve the overall yield as well as the convergency, the industrial route [7] introduced the fully elaborated side chain 34 by condensation with the previously described 1,4-diketone 31 (Scheme 5 and Scheme 6). The desired atorvastatin structure was then obtained in only three additional steps via acetal cleavage, ester hydrolysis and formation of the calcium salt.


Scheme 6: Convergent synthesis towards atorvastatin.

Sunitinib (36, Sutent) is Pfizer’s novel receptor tyrosine kinase inhibitor (RTK) approved in 2006 by the FDA for the treatment of both renal cell carcinoma and gastrointestinal stromal tumors. This drug has been suggested as a second-line therapy for patients developing mutation-related resistance to other cancer medications such as imatinib (Gleevec). Sunitinib binds to the inactivated, auto-inhibited conformation of the KIT kinase by partially occupying the space normally filled by the ADP’s adenine in the phosphorylated protein. The indolinone section is located in a deeper pocket with the heteroatoms being involved in H-bonding glutamate and tyrosine residues whilst the pyrrole ring and the diethylaminoethyl appendage are exposed to the solvent environment [8] (Figure 3).


Figure 3: Binding pocket of sunitinib in the TRK KIT.

Structurally, this medication consists of a complex pyrrole-substituted 2-indolinone core which can be prepared by a late stage aldol condensation between a 2-indolinone fragment 42 with the corresponding pyrrole aldehyde 41 (Scheme 7). The oxime functionality in compound 38, which is obtained by nitrosation of tert-butyl acetoacetate (37) [9], is reduced by zinc to give an unstable aminoketone intermediate. Subsequent enamine formation and ring closure affords the fully substituted pyrrole ring 40. Selective deprotection of the tert-butyl ester with concomitant decarboxylation yields ethyl 2,4-dimethylpyrrole-3-carboxylate which can be formylated at the free ring position by trimethyl orthoformate to yield the fully elaborated pyrrole aldehyde (41). The aforementioned aldol condensation unites both key fragments: Ester hydrolysis and amide formation complete the synthesis (Scheme 7).


Scheme 7: Synthesis of sunitinib.

An attractive alternative synthesis of sunitinib introduces the amide side chain earlier by ring opening of 4-methyleneoxetan-2-one (43) with N,N-diethylethane-1,2-diamine (44) [10]. The resulting β-keto amide 45 is then converted to the analogous pyrrole by condensation with the previously mentioned oxime 38 under reductive conditions. Deprotection and decarboxylation of the remaining tert-butyl ester produces the desired pyrrole intermediate, which upon treatment with Vilsmeier reagent undergoes a formal acylation. This product is not isolated but reacted directly with 41 in an aldol condensation to yield sunitinib (Scheme 8).


Scheme 8: Alternative synthesis of sunitinib.


The neuroamine transmitter serotonin contains an indole ring, so it is not surprising that indoles are a recurring theme in many drugs affecting central nervous system (CNS) function including antidepressants, antipsychotics, anxiolytics and antimigraine drugs, as well as psychedelic agents. Indole is also one of the best represented heterocyclic motifs present in the top selling pharmaceuticals, being found in eight of the top 200 drugs, with five of these belonging to the triptan family of antimigraine treatments. The classical Fischer indole synthesis is usually reported as one of the first choice routes to prepare these scaffolds. Drugs such as GSK’s serotonin receptor modulators sumatriptan (49, Imitrex) and zolmitriptan (50, Zomig) use the Fischer indole synthesis at a late stage in order to form the desired compound albeit in only low to moderate yields (Scheme 9).


Scheme 9: Key steps in the syntheses of sumatriptan and zolmitriptan.

However, in sumatriptan the indole product resulting from the Fischer synthesis can still react further which leads to the formation of by-products and significantly reduced yields. One way to minimise this was to protect the nitrogen of the sulfonamide group prior to indole formation [11]. This leads not only to an increased yield in the indole forming step (to 50%) but also facilitates chromatographic purification. The dimethylamino group can be present from the beginning of the synthesis or can be introduced via displacement of chloride or reduction of a cyano moiety. Alternatively, the dimethyl ethylene amine side chain can be introduced in position 3 via a Friedel–Crafts-type acylation. The resulting acid chloride is transformed in situ to the corresponding amide which on reduction with lithium aluminium hydride affords sumatriptan (Scheme 10) [12].


Scheme 10: Introduction of the N,N-dimethylaminoethyl side chain.

In the standard Fischer indole synthesis a hydrazine, which is most commonly derived from the corresponding diazonium salt, is reacted with a suitable carbonyl compound. Alternatively, the Japp–Klingemann reaction can be used to directly couple the diazonium salt with a β-ketoester to obtain a hydrazone which can then undergo indole ring formation (Scheme 11) [13].


Scheme 11: Japp–Klingemann reaction in the synthesis of sumatriptan.

As can be seen from Scheme 11 the indole 59 prepared via the Japp–Klingemann reaction is substituted at position 2 by an ester group which prevents reaction with electrophiles, thereby reducing the amount of undesired by-products. A simple sequence of hydrolysis and decarboxylation then affords sumatriptan [14].

All the reported methods for the synthesis of sumatriptan begin with the sulfonamide group already present on the aromatic ring and several routes are possible to introduce this functional group. The scalable route to the sulfonamides inevitably involves the preparation of the sulfonyl chloride intermediate which is then trapped with the desired amine. The sulfonyl chloride can also be prepared from the corresponding hemithioacetal 61 by treatment with NCS in wet acetic acid (Scheme 12). This efficient oxidation produces only methanol and formaldehyde as by-products [15].


Scheme 12: Synthesis of the intermediate sulfonyl chlorides 62 and 63.

Another possible approach is based on the direct displacement of a benzylic chloride by sodium sulfite and subsequent sulfonamide formation as shown in Scheme 13 [16].


Scheme 13: Alternative introduction of the sulfonamide.

A more recent method utilises a palladium-catalysed Negishi coupling to access a diverse library of benzylic sulfonamides, all prepared in high yields. As this route employs sulfonamide-stabilised anions the preparation and handling of unstable sulfonyl chloride intermediates is therefore circumvented (Scheme 14) [17].


Scheme 14: Negishi-type coupling to benzylic sulfonamides.

An analogous Heck reaction approach has also been employed to introduce a homologous side chain as demonstrated during the assembly of the antimigraine drug naratriptan (69, Amerge, Scheme 15) [18].


Scheme 15: Heck reaction used to introduce the sulfonamide side chain of naratriptan.

Another related antimigraine drug developed by GSK is zolmitriptan (Zomig, 50). The indole ring and its substitution at the 3-position are identical to that of sumatriptan, however, the sulfonamide side chain has been replaced by an oxazolinone ring. The original synthesis utilised 4-nitro-L-phenylalanine (73) as the precursor for the oxazoline moiety (Scheme 16) [19]. The resulting Fischer indole synthesis is similar to that used for sumatriptan (Scheme 9).


Scheme 16: Synthesis of the oxazolinone appendage of zolmitriptan.

More recent reports [20] deal with improvements to both these syntheses making them more economic and environmentally benign. For example, the three steps to zolmitriptan, namely, diazonium salt formation, its subsequent reduction and Fischer indole synthesis can all be carried out in aqueous media without the need for intermediate isolation. It has also been demonstrated that the reduction of the initially formed diazonium salt can be accomplished by using sodium metabisulfite (Na2S2O5) rather than using the more toxic stannous chloride or the less water soluble and more expensive sodium sulfite.

Preparation of the indole ring system in the antimigraine drug rizatriptan (76, Maxalt) makes use of the Grandberg variation of the Fischer indole synthesis as the final stage reaction to form the tryptamine-type moiety, via formation and re-opening of a tricyclic intermediate [21,22]. Although not a high yield process, this one pot sequence establishes the indole ring and the pendant primary amine group in a single operation (Scheme 17).


Scheme 17: Grandberg indole synthesis used in the preparation of rizatriptan.

However, the main disadvantage of this process is the need for high temperatures which leads to the formation of dimeric impurities and results in the requirement for extensive chromatographic purification. An improved process which circumvents the formation of such dimeric impurities involves the reduction of the intermediate diazonium salt with sodium sulfite and hydrochloric acid to form an easily isolable and crystalline phenylhydrazine sulfonic acid 81. The subsequent Fischer indole synthesis can then be performed cleanly at much lower temperatures (Scheme 18) and yields pure rizatriptan as its benzoate salt [23]. In addition, the use of precursor 82, already possesing the desired dimethylamino group, simplifies the reaction sequence and tunes the reactivity of the amine preventing it from participating in many side reactions.


Scheme 18: Improved synthesis of rizatriptan.

The indole core of rizatriptan can also be prepared by a palladium-catalysed coupling first reported by Larock [24]. The iodoaniline derivative 84 required for this approach can be readily synthesised from triazolomethyl aniline 83 by treatment with iodine monochloride in aqueous methanol. The bis-TES-protected butynol 85 was found to be the most efficient coupling partner and led smoothly to the desired indole 86. Subsequent removal of the TES-groups and introduction of a dimethylamino moiety furnishes the desired drug compound [25-27] (Scheme 19).


Scheme 19: Larock-type synthesis of rizatriptan.

Eletriptan (87, Relpax) is yet another indole-containing antimigraine drug. A process route for the synthesis of eletriptan published by Pfizer starts from a preformed bromo-indole 88 [28] (Scheme 20). In order to perform the acylation of the indole ring on larger scale, ethylmagnesium bromide and the corresponding acid chloride 89 are added concurrently from two different sides of the reactor to stop these reagents reacting with each other. This method of adding the reagents circumvents the necessity to isolate the magnesium salt of the indole and increases the yield from 50 to 82%. The carbonyl group of the proline side chain is then reduced simultaneously with the complete reduction of the Cbz-group to a methyl group with lithium aluminium hydride. Finally, the sulfonate side chain is introduced via a Heck-type coupling similar to that of naratriptan (Scheme 15), followed by hydrogenation of the double bond to afford eletriptan (Scheme 20).


Scheme 20: Synthesis of eletriptan.

A rather ingenious Mitsunobu coupling reaction has been used to create a highly functionalised substrate 96 for an intramolecular Heck reaction resulting in a very short and succinct synthesis of eletriptan and related analogues 97 [29] (Scheme 21).


Scheme 21: Heck coupling for the indole system in eletriptan.

Interestingly, it was found that the most obvious approach, the direct Fischer indole synthesis, to prepare the core of eletriptan as shown in Scheme 22 is not successful [30]. This is believed to be due to the instability of the phenyl hydrazine species 98 under the relatively harsh reaction conditions required to promote the cyclisation.


Scheme 22: Attempted Fischer indole synthesis of elatriptan.

However, this problem could be avoided by using an acid-labile oxalate protected hydrazine 104 as depicted in Scheme 23. The yield of this step can be further improved up to 84% if the corresponding calcium oxalate is used.


Scheme 23: Successful Fischer indole synthesis for eletriptan.

The Bischler–Möhlau reaction is an alternative indole synthesis employing an α-bromo ketone and an excess of aniline to give a 2-arylindole derivative 110 [31] (Scheme 24). For a long time this procedure has received little attention due to the requirement for rather extreme reaction conditions. However, the use of microwave radiation in combination with Lewis acid catalysis allows the reaction to be conducted much more efficiently [32]. This gives mid range yields (50–70%) of the 2-arylindoles over the two step sequence and tolerates a selection of functional groups on the aniline ring.


Scheme 24: Mechanistic rationale for the Bischler–Möhlau reaction.

Fluvastatin (2, Lescol), a HMG-CoA reductase inhibitor was initially prepared by a Fischer indole synthesis [33] (Scheme 25). However, in the development stages it was decided that a Bischler–Möhlau type reaction could be used instead. In this case a ZnCl2-mediated Bischler-type indole synthesis [34] is used with stoichiometric amounts of the aniline which leads to the required 3-substituted indole core 116 at an early stage in the synthesis. A novel way to introduce a formyl substituent at the 2-position of the indole was subsequently developed to aid the introduction of the syn-diol pendant side-chain.


Scheme 25: Bischler-type indole synthesis used in the fluvastatin sodium synthesis.

A completely different strategy was used in the synthesis of the serotonin 5-HT3 receptor antagonist ondansetron (119, Zofran). In this synthesis a palladium-catalysed intramolecular Heck-reaction was used to build the tricyclic indole core in a short and concise sequence (Scheme 26) [35,36].


Scheme 26: Palladium-mediated synthesis of ondansetron.

Alternatively, a direct Fischer indole synthesis between phenylmethyl hydrazine and a cyclic 1,3-dione derivative could be utilised to prepare the desired fully substituted tricyclic core of ondansetron (Scheme 27) [37].


Scheme 27: Fischer indole synthesis of ondansetron.

A different approach was used in the synthesis of the phosphodiesterase inhibitor tadalafil (132, Cialis) starting from commercially available (D)-tryptophan methyl ester to form the indolopiperidine motif 135 via a Pictet–Spengler reaction followed by a double condensation to install the additional diketopiperazine ring (Scheme 28) [38,39].


Scheme 28: Optimised Pictet–Spengler reaction towards tadalafil.

To achieve the high levels of cis selectivity required from the Pictet–Spengler reaction, an extensive investigation of solvents and the influence of additives was undertaken [40]. It was identified that the use of a specific 23 mol % of benzoic acid significantly increased the cis/trans ratio from a base level of 55:45 to 92:8 (16 h reaction time at ambient temperature) in an overall yield of 86%. It was also determined that more polar solvents such as acetonitrile and nitromethane preferentially solvated the trans product and thereby allowed the isolation of the cis compound by precipitation. It was also shown that by heating the reaction mixture under reflux the product distribution could be driven to the thermodynamically more favoured cis isomer having both the ester and the piperonyl moiety in equatorial positions. Hence, after heating under reflux for 8 h the cis/trans ratio was found to be 99:1 and the product could be isolated in an overall yield of 91%. This work represents an impressive example of a well considered and executed process optimisation study.


Carvedilol (136, Coreg) is a general non-selective β-blocker, used in the treatment of mild to moderate congestive heart failure. The structure comprises of a core carbazole ring that plays an important role in its increased activity.

The cardioprotective effect of β-adrenergic blockers is attributed to their ability to reduce the myocardial workload by reducing the system’s requirement for oxygen. However, the activity of carvedilol is greater when compared to other members of the β-blocker family such as propranolol (137, Figure 4) implying that carvedilol has an additional antioxidant mode of action. It has been proposed that the carbazole ring may be involved in scavenging oxygen radicals thereby accounting for reduced myocardial damage [41].


Figure 4: Structures of carvedilol 136 and propranolol 137.

Since carbazoles are similar to indoles, analogous methods can be used for their synthesis. The key intermediate for carvedilol is 4-hydroxy-9H-carbazole (141) [42]. In analogy to the Fischer indole synthesis, cyclohexane-1,3-dione monophenyl hydrazone 139 is prepared via condensation of phenylhydrazine (138) with 1,3-cyclohexanedione (121, Scheme 29). This compound can then undergo an acid catalysed Fischer indole synthesis to yield tetrahydro-4-oxocarbazole 140. Various methods have been described to dehydrogenate this intermediate including the use of bromine, sulfur, LiCl/CuCl, lead dioxide, chloranil or palladium on charcoal. However, the need to use these reagents in equal stoichiometry or even excess has led to the search for a new approach. It was found that a catalytic quantity of Raney nickel in an aqueous potassium hydroxide solution gives the desired 4-hydroxy compound 141 cleanly and in high conversion (Scheme 29).


Scheme 29: Synthesis of the carbazole core of carvedilol.

Alternative routes to this key intermediate such as Ullmann-type reactions have also been reported, however, these usually rely on longer reaction sequences and require more expensive starting materials (Scheme 30) [42,43].


Scheme 30: Alternative syntheses of 4-hydroxy-9H-carbazole.

Etodolac (153, Lodine) is a racemic non-steroidal anti-inflammatory tetrahydrocarbazole derivative used to treat inflammation and prescribed for general pain relief. Two general routes have been described for the preparation of this drug. In the first route the hydrazine 149 is prepared via the reduction of diazonium salt 148 with tin(II) chloride and subjected to a Fischer indole reaction with aldehyde 150. The resulting indole is then condensed with ethyl 3-oxopropanoate followed by saponification of the ester to yield etodolac (Scheme 31) [44].


Scheme 31: Convergent synthesis of etodolac.

The second described route [45,46] is similar but starts with a more readily available carbonyl surrogate; 2,3-dihydrofuran 154. The Fischer indole reaction provides a primary alcohol which is TMS-protected and condensed with methyl 3-oxopentanoate under Lewis acid conditions. The use of the temporary silyl mask was found beneficial as it circumvents the need for chromatographic purification. Finally, simple saponification furnishes etodolac (Scheme 32).


Scheme 32: Alternative synthesis of etodolac.

Extensive biological studies have found that the majority of the reactivity of etodolac is derived from the (S)-(+)-enantiomer. The resolution of the racemate can be readily accomplished using cinchonine or the glucose derivative N-methyl-D-glucamine. The latter provides the pure (S)-(+)-enantiomer in 25.3% yield (>96% de) after two crystallisations. In addition, the racemisation of the undesired enantiomer via methyl ester formation and treatment with sodium hydroxide was found to be feasible allowing efficient recycling of this material [47].


Imidazole is an important biological building block being present in the amino acid histidine and possessing inherent catalyst and acid–base functionality. An imidazole ring is also a component of the biogenic amine histamine. It is interesting to note that the imidazole ring does not however appear in the most common H1 and H2 antagonists, presumably due to its metabolic vulnerability, with cimetidine being an exception. The use of such compounds has now been almost completely superseded by the prescription of alternative proton pump inhibitors such as esomeprazole.

Imidazole containing drugs can be subdivided into two classes: monocyclic imidazoles and benzimidazoles. The former is represented by three drugs targeting hypertension losartan (157, Cozaar), olmesartan (158, Benicar), eprosartan (159, Eprozar) as well as nausea (ondansetron (119, Zofran)) (Figure 5). All of these drugs aptly highlight a different synthetic approach to the imidazole core. Early antagonists of the angiotensin II receptor were of a peptidic nature, suffered from poor bioavailability and also showed some agonistic activities. The first non-peptide antagonists were developed in the early 80’s. Although these compounds were selective for the AT2 receptor, they bound only weakly to their target protein. On examining the angiotensin II amino acid sequence, researchers took notice of an acidic residue on the NH2 terminus. Consequently, a carboxylic acid moiety was added to the designed ligand improving affinity for the AT2 receptor. However, the polar nature of the carboxylic acid group caused this compound to suffer from poor absorption and low bioavailability. At this stage a classical bioisostere exchange, i.e., replacing a carboxylic acid group with a tetrazole ring, was performed which resulted in increased lipophilicity [48] and the development of the orally active losartan.


Figure 5: Structures of imidazole-containing drugs.

In the absence of a crystal structure, mutation studies have shown that the AT2 antagonists such as losartan bind to an active site located within the membrane-bound part of the receptor, which is different to that of the peptide agonist. Further studies led to the discovery of valsartan, where the imidazole ring of losartan is replaced by an N-acylated amide which is suggested to mimic the C-terminus of angiotensin II [49].

The imidazole ring of losartan, an antihypertensive and angiotensin II blocker is formed in a condensation reaction between valeroamidine 160 and dihydroxyacetone [50]. It was found that direct chlorination of the imidazole 162 also forms the dichlorination product 164 (as shown in Scheme 33) with formaldehyde as a by-product which proved difficult to suppress and made purification of the reaction mixture problematic. Hence, a sequence involving silyl protection, chlorination and deprotection was established which gave the desired product in 90% overall yield (Scheme 33).


Scheme 33: Synthesis of functionalised imidazoles towards losartan.

Alternatively, glycine can be reacted with methyl pentanimidate 169 to form the corresponding amidine 171 in high yield. Cyclisation, followed by a Vilsmeier-type reaction then furnishes the key chloroimidazolyl building block 172 in good yield (Scheme 34) [51].


Scheme 34: Direct synthesis of the chlorinated imidazole in losartan.

More recently, Zhong and co-workers [52] reported a highly efficient one-pot procedure starting from N-acylated α-aminonitriles 173. The desired 2,4,5-trisubstituted imidazole core 178 is formed in high yield in the presence of carbon tetrachloride and triphenylphosphine (Scheme 35). Mechanistic studies showed that the related imidoyl compounds do not themselves undergo ring closure to form imidazoles and it was therefore proposed that the reaction between carbon tetrachloride and triphenylphosphine to generate dichlorotriphenylphosphorane and (dichloromethylene)triphenylphosphorane was pivotal. The amidonitrile substrate 173 can then react with both species to form seven-membered cyclic intermediate 175 which collapses to form the imidazole compound.


Scheme 35: Synthesis of trisubstituted imidazoles.

The structurally related imidazole core of olmesartan is formed in a different fashion (Scheme 36). Condensation between diaminomaleonitrile and trimethyl orthobutyrate furnishes the trisubstituted imidazole 181 in high yield [53,54]. Acid-mediated nitrile hydrolysis followed by esterification results in the corresponding diester unit 182. Treatment of 182 with four equivalents of methylmagnesium chloride in a mixture of diethyl ether and dichloromethane selectively provides tertiary alcohol 183. In subsequent steps this imidazole is alkylated with the tetrazole containing biphenyl appendage, followed by ester hydrolysis and alkylation of the resulting carboxylate with 4-(chloromethyl)-5-methyl-2-oxo-1,3-dioxole to yield olmesartan (Scheme 36).


Scheme 36: Preparation of the imidazole ring in olmesartan.

The imidazole motif present in ondansetron (119), a prototypic 5-HT3 receptor antagonist, is incorporated into the molecule by substitution of a trimethylammonium functionality of an advanced intermediate 188 by 2-methylimidazole (187, Scheme 37) [55]. Alternatively, this substitution can be performed on a cyclohexenone derivative prior to the Fischer indole synthesis (Scheme 27) [38]. The required imidazole 187 itself can be prepared via a variety of methods. For example, a process involving acetaldehyde, glyoxal and ammonium carbonate furnishes the desired compound in an excellent 95% yield (Scheme 37). Also, a condensation reaction between ethylenediamine and acetic acid catalysed by γ-Al2O3 at high temperatures gives 2-methylimidazole (187) in approximately 90% yield [56].


Scheme 37: Synthesis of ondansetron.

Elz and Heil [57] prepared the 1,2,3,9-tetrahydro-4H-carbazol-4-one (140) by the reaction of phenylhydrazine (138) with cyclohexan-1,3-dione (Scheme 38). Classical N-methylation with dimethyl sulfate followed by introduction of an exocyclic double bond using paraformaldehyde in DMF under acidic conditions furnishes the Michael acceptor 189, which then undergoes conjugate addition with various amines (Scheme 38). This route has been used to prepare several ondansetron analogues based on different amine components.


Scheme 38: Alternative route to ondansetron and its analogues.


Nearly all benzimidazole containing drugs such as esomeprazole (190, Nexium), omeprazole (191, Prilosec), lansoprazole (192, Prevacid), pantoprazole (193, Protonix) and rabeprazole (194, Aciphex) are proton pump inhibitors. The common feature in their synthesis is the double condensation of a 1,2-diaminobenzene with potassium ethylxanthate (196) [58]. A typical synthesis of the methoxybenzimidazole system present in esomeprazole (omeprazole) and lansoprazole is shown in Scheme 39. For esomeprazole the subsequent steps involve an S-alkylation as well as an asymmetric oxidation of the newly formed thioether [59,60].


Scheme 39: Proton pump inhibitors and synthesis of esomeprazole.

Additional structural diversity in the aniline component can be introduced by protection, nitration, deprotection and reduction of the starting amine compound 201. Scheme 40 for instance shows this in the synthesis of the benzimidazole core of pantoprazole [61].


Scheme 40: Synthesis of benzimidazole core pantoprazole.

The benzimidazole ring in rabeprazole (194, Figure 6) is only substituted at position 2 and can be easily prepared by the same procedure.


Figure 6: Structure of rabeprazole 194.

In a similar strategy, the benzimidazole structure 210 in the angiotensin II antagonist candesartan (204, Atacand) is formed from an advanced diaminobenzene derivative, which in turn is prepared by a tin-mediated nitro reduction to form a highly substituted diaminobenzene (Scheme 41). This general strategy involving initial alkylation of 207 is often employed to control the regioselectivity of the imidazole formation. The benzimidazole ring is then assembled by treating this diamine with tetraethyl orthocarbonate under Lewis acid conditions. The synthesis is concluded by installation of the tetrazole ring and acetal side chain, the latter is cleaved under physiological conditions, making candesartan a pro-drug in the same way as olmesartan [62]. This synthesis of the benzimidazole precursor makes use of a 1,2,3-trisubstituted nitrophthalic acid 205, which had to be selectively monoesterified and subjected to a Curtius rearrangement, which is cumbersome when the reaction is scaled up. Alternative routes to such trisubstituted benzenes include directed ortho-lithiation of 1,3-disubstituted benzenes followed by trapping of the anion with a nitrogen electrophile [63]. As a result a new route to access the key building block has been proposed which makes use of a less widely utilised acid catalysed rearrangement of methyl N-nitroanthranilate (212) which is obtained by N-nitration of methyl anthranilate (211, Scheme 42). Alkylation of the intermediate with the biphenylmethyl bromide 208 under mildly basic conditions yields adduct 213. Upon treatment of this compound with 80% aqueous sulfuric acid a rearrangement to furnish a mixture of the 3- and 5-nitro derivatives occurs, which unfortunately at this stage, could not be separated by crystallisation. However, when this mixture was subjected to catalytic hydrogenation with Raney nickel a separable mixture of the corresponding diaminobenzoates was obtained (Scheme 42) [64].


Scheme 41: Synthesis of candesartan.


Scheme 42: Alternative access to the candesartan key intermediate 216.

Telmisartan (217, Micardis) is a well known angiotensin II receptor antagonist used in the treatment of hypertension and, heart and bladder diseases. Its pharmacophore consists of two linked benzimidazoles and a biphenyl unit (Scheme 43). As shown previously, such benzimidazoles can be formed through the condensation reaction of a 1,2-diaminobenzene and a suitable functionalised carbonyl compound. However, in the case of telmisartan other inherent functionalities such as an ester are present which leads to the formation of several by-products and consequently significantly lower yields. Another obvious drawback of the initially described route [65] when considering scale up, is the number of sequential steps in the synthesis (8 steps, 21% overall yield) (Scheme 43).


Scheme 43: .Medicinal chemistry route to telmisartan.

Hence an improved synthesis was sought [66]. This revised route utilised a palladium-mediated reduction of the highly substituted nitrobenzene derivative 219 to afford aniline 224 which under basic conditions ring closes to the corresponding benzimidazole 225. Under the same reaction conditions, the hydrolysis of the methyl ester also occurs which allows the introduction of the second imidazole group in the subsequent condensation step. Sterically directed alkylation of the free imidazole nitrogen with the required biphenyl derivative 223 in basic media yields the methyl ester 226 which is isolated, after work-up and solvent removal, as the hydrochloride salt in 85% yield. HPLC analysis showed a purity of >99.5% which is by far superior to the previously reported synthesis [65]. Finally, hydrolysis of the methyl ester provides telmisartan in an overall yield of about 50% compared to 21% as previously obtained (Scheme 44).


Scheme 44: Improved synthesis of telmisartan.


Zolpidem (227) is a non-benzodiazepine hypnotic, and is part of the imidazopyridine class of pharmaceuticals. It is an agonist for the target receptor of γ-aminobutyric acid (GABA), an inhibitory neurotransmitter. Zolpidem binds to GABA receptors at the same site as typical benzodiazepines. This drug is preferred to benzodiazepines for long term use since benzodiazepines lead to a higher tolerance as well as physical dependence. The standard route to this scaffold is the cyclocondensation of a functional 2-aminopyridine with an α-bromo-carbonyl compound [67,68]. In the case of zolpidem, the amide moiety in the 3-position of the ring system is introduced via a Friedel–Crafts/Mannich-type alkylation starting either from formaldehyde and dimethylamine or 2,2-dimethoxy-N,N-dimethylacetamide (Scheme 45).


Scheme 45: Synthesis of zolpidem.

In a recent study a more straightforward and general copper-catalysed three component coupling leading to imidazopyridines has been reported [69]. For this reaction 2-amino-5-methylpyridine (228) was condensed with an aldehyde to form an intermediate imine to which is added a terminal alkyne in the presence of copper(I) chloride. A copper(II) triflate catalyst is then used to promote a Lewis acid promoted 5-exo-dig heteroannulation to furnish, after chromatography, the bicyclic structure in good overall isolated yield (Scheme 46).


Scheme 46: Copper-catalysed 3-component coupling towards zolpidem.

Despite this synthesis being much shorter and convergent it has some limitations since the entire procedure needs to be performed in a glove box and has consequently only been reported on small scale.


Selective inhibitors of cyclooxygenase-2 (COX-2) are widely used for their anti-inflammatory effects and have shown less gastrointestinal side effects when compared to other anti-inflammatory agents, notably non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin and ibuprofen, which inhibit both COX-1 and COX-2. The central ring is usually a five-membered aromatic system, which is diaryl-substituted with a (Z)-stilbene-like linking structure. A polar sulfonamide group or biologically equivalent unit is usually present at the para-position of one of the aryl rings and is believed to promote binding to a hydrophilic pocket close to the active site of COX-2. Celecoxib (235, Celebrex, Figure 7) belongs to the group of selective COX-2 inhibitors acting on the prostaglandin G/H synthase 2 as well as 3-phosphoinositide-dependent protein kinase 1 and is marketed by Pfizer. Interestingly, celecoxib has also been approved for familial adenomatous polyposis demonstrating its ability to induce apoptosis in certain cancer cell lines [70]. As this activity is not shared with all COX-2 inhibitors, it is believed that the structural features such as the polar sulfonamide group, the lipophilic tolyl moiety and the trifluoromethylated pyrazole core with its negative electrostatic potential play a key role in apoptosis induction. Consequently, the anti-inflammatory and apoptosis inducing properties of celecoxib are assumed to result via different modes of action.


Figure 7: Structure of celecoxib.

In a recent study [71], celecoxib has also been shown to be a rapid, freely reversible, competitive inhibitor of COX-1. This result was supported by X-ray crystallographic evidence, where celecoxib was shown to bind to one subunit of the COX-1-dimer, implying that drugs like aspirin then bind to the other monomer of the same enzyme consequently slowing down the irreversible acetylation of a serine residue by aspirin itself. This finding is relevant as aspirin is clinically used in combination with celecoxib to attenuate its cardiovascular side effects. Based on this in vitro study, it is suggested that the cardioprotective effects of low-dose aspirin on COX-1 might be reduced when administered with celecoxib. Further studies are currently underway to elucidate the full sympathetic action of co-administration.

The common synthetic route to the diarylpyrazole ring of celecoxib (235) is a direct condensation of the 1,3-dicarbonyl compound 236 and the substituted hydrazine 237 [72,73] (Scheme 47).


Scheme 47: Preparation of celecoxib.

The immediate downside to this approach is the generation of regioisomeric mixtures. However, this is often of minor concern. In the commercial process only 2–5% of the unwanted regioisomer is produced, with the purified pyrazole being obtained by crystallisation. It has been claimed that minimising the diketone’s exposure to water prior to its reaction with the hydrazine significantly reduces the formation of the unwanted regioisomer by avoiding the formation of a hydrate at the carbonyl bearing the more electronegative CF3-group. Alternatively, in order to circumvent the regioselectivity issue, other pyrazole syntheses have been used. For example, the substituted aryl hydrazine 237 can be reacted with trifluoromethyl butynone in a one pot reaction. A Michael addition/cyclisation sequence renders only the desired regioisomer of the pyrazole [74]. However, preparation of the alkyne intermediates involves a number of steps and often requires extensive column chromatography, which makes it an unattractive method for synthesis on a larger scale (Scheme 48).


Scheme 48: Alternative synthesis of celecoxib.

A novel 1,3-dipolar cycloaddition between a nitrile imide 244 and an appropriately substituted olefin 245 has also been used to obtain the corresponding trisubstituted pyrazole [75]. The final synthesis and its dipole precursor are represented in Scheme 49.


Scheme 49: Regioselective access to celecoxib.

Since this is a LUMO-dipole/HOMO-dipolarophile controlled reaction, an electron-rich alkene is required. Therefore, when the morpholine derived enamine 245 was used the desired 1,3,5-substituted pyrazole was formed with 100% regioselectivity (Scheme 49). This high regioselectivity is only obtained when a 1,1-disubstituted enamine is used, the corresponding 1,2-disubstituted enamine yields mainly the other regioisomer.


Pazopanib (246, Votrient) is a new potent multi-target tyrosine kinase inhibitor for various human cancer cell lines. Pazopanib is considered a promising replacement treatment to imatinib and sunitinib and was approved for renal cell carcinoma by the FDA in late 2009. The indazole system is built up via diazotisation and spontaneous cyclisation of 2-ethyl-5-nitroaniline (247) using tert-butyl nitrite. The resulting indazole structure 249 can be methylated entirely regioselectively with either Meerwein’s salt, trimethyl orthoformate or dimethyl sulfate. A tin-mediated reduction of the nitro group unmasks the aniline which undergoes nucleophilic aromatic substitution to introduce the pyrimidine system with the formation of 253. Methylation of the secondary amine function with methyl iodide prior to a second SNAr reaction with a sulfonamide-derived aniline affords pazopanib (Scheme 50) [76,77].


Scheme 50: Synthesis of pazopanib.


Although many common antifungal drugs contain at least one 1,2,4-triazole ring, barely any of these drugs are represented in the top 200 drugs based on the value of sales. This observation obviously reflects more the price differential of the drug class rather than the utility of the heterocycle. In general, the triazole containing drugs belong to two groups of therapeutic agents: selective and non-steroidal aromatase inhibitors which are used in the treatment of early and advanced breast cancer in postmenopausal women, e.g., letrozole (256, Femara) and anastrozole (257, Arimidex) and 5-HT1 agonist triptan drugs such as rizatriptan (76, Maxalt) which are prescribed for migraine headaches. The large scale syntheses of all these compounds use the commercially available 1,2,4-triazolyl sodium salt 258 in an alkylation reaction with the corresponding benzyl bromide derivative as the key step (Scheme 51) [78].


Scheme 51: Syntheses of anastrozole, rizatriptan and letrozole.

One major problem with this route towards anastrozole (257) (Scheme 51) is the formation of the non-desired regioisomer, which is often produced in between 10–20% and must be removed by means of crystallisation which results in a major loss of material [79]. In order to circumvent the formation of the undesired regioisomer, a strategy that is often used is to react the corresponding benzyl bromide component first with 4-amino-1,2,4-triazole (266) to form a quaternary ammonium salt. The latter can be deaminated to give anastrozole with no isomeric impurities (Scheme 52) [79].


Scheme 52: Regioselective synthesis of anastrozole.

Other synthetic routes to 1,2,4-triazoles have also been reported. For example, the desired triazole ring of anastrozole can be obtained by reacting an appropriately substituted hydrazine hydrochloride salt 269 with triazine (270) (Scheme 53) [80].


Scheme 53: Triazine-mediated triazole formation towards anastrozole.

It has been proposed that this novel transformation occurs by a two step process: Initially, a molecule of triazine undergoes condensation and ring cleavage with the hydrazine to generate formamidrazone 271 which then immediately reacts with a second molecule of triazine to yield the 1,2,4-triazole [81]. Hence, in this case the triazine can be considered as a formamide donor.

Rizatriptan (76) has also been prepared by both the above mentioned procedures, i.e., via the pre-made triazole or by treatment of a hydrazine hydrochloride salt with triazine (Scheme 54) [82]. Indeed, the latter protocol has been further expanded to make use of additional formamide surrogates such as a formamidinium salt 273 or Gold’s reagent (274) (Scheme 54).


Scheme 54: Alternative routes to 1,2,4-triazoles.

Sitagliptin (275, Januvia) is a recently developed oral anti-diabetic drug which belongs to the dipeptyl peptidase DPP-IV inhibitor class. The inhibition of DPP-IV leads to increased incretin levels and the inhibition of glucagon release. Consequently, insulin secretion increases leading to decreased blood glucose levels in diabetes type II patients. Structurally, this novel antihyperglycaemic consists of a fluorinated β-amino acid which is coupled to a trifluoromethylated triazolopiperazine (Scheme 55). In SAR studies this fused heterocycle was found to be more metabolically stable compared to earlier leads that contained a simple piperazine ring. Furthermore, the triazolopiperazine is not only involved in a tight H-bond network within the active site of DPP-IV, but also in π-stacking with the aromatic ring of a nearby phenylalanine residue, whilst the trifluoromethyl group interacts with serine and arginine residues in a lipophilic pocket (Figure 8) [83].


Scheme 55: Initial synthetic route to sitagliptin.


Figure 8: Binding of sitagliptin within DPP-IV.

In the discovery chemistry route [84] the heterocycle core was prepared from a SNAr reaction between chloropyrazine (276) and excess hydrazine. Subsequent treatment of the substituted intermediate with trifluoroacetic anhydride furnished the corresponding bis-hydrazide 278 which underwent cyclisation at elevated temperatures in the presence of polyphosphoric acid. Finally, the partial hydrogenation of triazolopyrazine derivative 279 with palladium on carbon gave the core triazolopiperazine 280. This was then coupled with carboxylic acid unit 281 under standard peptide bond forming conditions and subjected to palladium catalysed debenzylation to liberate the free amine functionality of sitagliptin (275) (Scheme 55).

An inherent problem with this synthesis was the necessity for excess hydrazine in the first step of the sequence in addition to a requirement for an expensive and only moderately efficient palladium reduction in the penultimate step. Furthermore, the chloropyrazine starting material also proved to be unstable under a series of reaction conditions and gave rise to numerous by-products. An improved route was developed for the compounds large scale manufacture. The refined process route (Scheme 56) starts with a sequential bis-acylation of hydrazine with ethyl trifluoroacetate and chloroacetyl chloride [85]. The resulting hydrazide 283 was then subjected to cyclodehydration using phosphoryl chloride to give a chloromethyl oxadiazole derivative 284. In a cleverly staged transformation, this compound was treated with diaminoethane to yield the piperazine ring 285, which, on heating under reflux in methanol, undergoes a further condensation with the attached hydrazide to furnish the desired triazolopiperazine ring 280 directly.


Scheme 56: The process route to sitagliptin key intermediate 280.

A novel and very promising HIV treatment is Pfizer’s maraviroc (286, Celsentri). HIV uses a member of the G-protein coupled receptor family called CCR-5 as an anchor to attach itself to white blood cells such as T-cells and macrophages followed by viral fusion and entry into white blood cells. Maraviroc blocks this pathway by acting as an antagonist for the CCR-5 receptor hence disrupting HIV life cycle. The structural features of this molecule are a geminal difluorocyclohexyl carboxamide which is linked to a β-aminoacid, and a tropinone-type unit bound to a 1,2,4-triazole ring. Relatively simple and straightforward chemical transformations are used to assemble the main fragments of maraviroc such as amide bond formation and reductive amination (Scheme 57) [86]. The triazole ring incorporation is achieved at an early stage by N-acylation of the tropinone fragment 287 with 2-methylpropanoyl chloride (288). The resulting amide 289 is then converted to the corresponding imidoyl chloride 290 using phosphorous pentachloride in dichloromethane (which proved to be superior to phosphoryl chloride) followed by condensation with acetic hydrazide (291). It was found that the dryness of the acetic hydrazide was crucial in order to minimise the hydrolysis of the starting amide 289.


Scheme 57: Synthesis of maraviroc.

Benzodiazepines are a well known class of compounds with a wide range of CNS-related activities. Moreover, the attachment of a third ring has been found to impact greatly on the pharmacological profile of these drugs. A representative of this compound class is alprazolam (297, Xanax) which contains a 1,2,4-triazole fused to the benzodiazepine core. The synthesis of this molecule [87,88] (Scheme 58) can be accomplished in a short sequence of steps starting by acylation of 2-amino-5-chlorobenzophenone (298) with chloroacetyl chloride (281) to give the amide derivative 299. The latter undergoes an interesting ring closure reaction in the presence of hexamine and ammonium chloride and the resulting seven membered lactam 300 can then be converted into its thioamide analogue 301 with P2S5 in pyridine. Finally, the reaction of 301 with acetyl hydrazide (291) catalysed by acetic acid furnishes the triazole ring fused to the benzodiazepine core.


Scheme 58: Synthesis of alprazolam.

Another approach [89] makes use of 1,4-benzodiazepine-N-nitrosamidine 302 as the starting material which when treated with acetyl hydrazide (291) undergoes the final ring closure. This procedure can also be employed to prepare the related series of imidazobenzodiazepines if TosMIC (303) or the aminopropanol 304 are used as nucleophiles (Scheme 59).


Scheme 59: The use of N-nitrosoamidine derivatives in the preparation of fused benzodiazepines.

Triazole containing antifungal compounds (Figure 9) are a well known group of pharmaceuticals but only a few members are represented in the list of best selling drugs, e.g., itraconazole (307, Sporanox), ravuconazole (308, BMS-207147) and voriconazole (309, Vfend).


Figure 9: Structures of itraconazole, ravuconazole and voriconazole.

All members of this class share a common biological activity being inhibitors of fungal cytochrome P-450 oxidase-mediated synthesis of ergosterol. Itraconazole, marketed by Janssen Pharmaceuticals, consists of two triazole subunits as well as a central diarylpiperazine unit (Figure 9). In one synthesis of itraconazole [90] 1,2,4-triazole was introduced via direct nucleophilic substitution. However, due to the previously discussed regioselectivity issues, extensive chromatographic purification was required following this step. In the latter stages of the synthesis, the elaborated aniline derivative 310 was trapped with phenyl chloroformate to form the corresponding carbamate which was then converted into triazolone 314 by a double condensation reaction with hydrazine and formamidine. Finally, simple attachment of an isobutyl group completes the synthesis (Scheme 60).


Scheme 60: Synthesis of itraconazole.


Rufinamide (315, Inovelon) is Novartis’ new CNS-active compound used in the treatment of epilepsy. The common route [91,92] to the triazole ring present in this compound involves the reaction of 2,6-difluorobenzyl azide (316) with 2-chloro acrylonitrile 317 at temperatures around 80 °C in aqueous medium (Scheme 61). This transformation, which can be described either as a conjugate addition–elimination sequence or as a [3 + 2] cycloaddition followed by elimination was found to work best in a biphasic system, where the resulting HCl was retained in the aqueous phase thereby reducing overall amounts of polymerisation of the 2-chloroacrylonitrile starting material. In the final step the nitrile group is quantitatively hydrolysed under basic conditions to the primary amide.


Scheme 61: Synthesis of rufinamide.

Apart from this patented route, an improved approach has recently been described [93]. In this work it was shown that the highly toxic and flammable 2-chloroacrylonitrile can be readily substituted with the less toxic and less expensive methyl 3-methoxyacrylate. After thermal cycloaddition, the methyl ester is converted to the corresponding amide by the addition of methanolic ammonia. Overall, this process can be performed as a single pot procedure on a multi-gram scale to afford rufinamide in a similarly high yield and generating less waste.


The tetrazole motif as a bioisostere for a carboxyl group is a well documented structural replacement represented by five angiotensin II antagonists in the top selling 200 drugs. In order to generate the tetrazole ring, a nitrile is reacted with an azide, most commonly tributyltin azide. This is illustrated by the Novartis/Ciba-Geigy synthesis of valsartan (319, Diovan), where the tetrazole ring is constructed in the last step of the sequence (Scheme 62) [49].


Scheme 62: Representative tetrazole formation in valsartan.

The same approach is repeated in other angiotensin AT2 antagonists, such as olmesartan (158), candesartan (204) or irbesartan (321) (Figure 10).


Figure 10: Structure of tetrazole containing olmesartan, candesartan and irbesartan.

The tetrazole ring has also been introduced at the beginning of the synthesis, however, the heterocyclic ring, which has to be carried through all subsequent steps, often requires protection. One common protecting group is the trityl group as used in the synthesis of losartan (157) (Scheme 63) [51,94].


Scheme 63: Early stage introduction of the tetrazole in losartan.

The tetrazole ring also appears in cilostazol (325, Pletal) which is a selective PDE3 phosphodiesterase inhibitor used as a platelet aggregation inhibitor. The tetrazole ring 327 is prepared via the reaction of an in situ generated imidoyl chloride and hydrazoic acid delivered as a 10% solution in benzene [95,96]. Subsequent alkylation under Williamson conditions provides the final compound 325 in good yield (Scheme 64).


Scheme 64: Synthesis of cilostazol.


The first example of a thiazole in the top 200 drugs listings is cefdinir (329, Omnicef, Figure 11), a semi-synthetic third generation cephalosporin which is administered orally and has an extended antibacterial activity against both gram-positive and gram-negative bacteria. The main feature of cefdinir is that it shows excellent activity against Staphylococcus species [97]. The thiazole ring in cefdinir shows that the heterocyclic structure in a drug not only affects its pharmacodynamic properties but can also influence its kinetics. It is believed that in the digestive tract iron(II) ions form chelate complexes with the thiazole ring and the oxime nitrogen atom and hence reduce the bioavailability of cefdinir [98].


Figure 11: Structure of cefdinir.

The convergent semi-synthesis of cefdinir can be achieved by coupling 7-amino-3-vinyl-3-cephem-4-carboxylic acid ester 335 with an advanced carboxylic acid derivative 334 which contains the elaborated thiazole motif (Scheme 65). This heterocyclic acid can itself be obtained from ethyl acetoacetate which is converted to an oxime 330 and α-chlorinated prior to a Hantzsch-type thiazole synthesis with thiourea in ethanol and N,N-dimethylaniline as the base [99]. Simultaneous trityl protection of the oxime and primary amine furnishes the desired coupling partner 334 in good overall yield. Hydroxide promoted ester hydrolysis was followed by treatment with phosphoryl chloride and the resulting acyl chloride coupled with the biologically derived lactam 335. All three trityl protecting groups are simultaneously cleaved with TFA to furnish cefdinir 329.


Scheme 65: Semi-synthesis of cefdinir.

The HIV-1 protease inhibitor ritonavir (337, Norvir, Scheme 66) consists of two differently substituted thiazole rings, which are introduced at the later stages in the synthesis of this peptidomimetic antiviral compound. Interestingly, ritonavir itself is a result of further improvements on earlier candidates for the treatment of AIDS. A lead compound (344, A-80987) was also described by Abbott bearing pyridine rings on both ends of the peptidomimetic structure, which resulted in good bioavailability as required for orally administered drugs, but this compound had an insufficient plasma half-life. This was ascribed to the more electron-rich nature of the pyridine rings when compared to many other nitrogen containing heterocycles leading to a higher metabolic susceptibility. Consequently, the pyridine rings were replaced with less electron-rich thiazoles which resulted in both good bioavailability and a long plasma half-life. In addition, H-bonding of the 5-substituted thiazole to the backbone of Asp-30 of the HIV-1 protease is reported to be crucial with other substitution patterns showing reduced potency. The thiazole on the left-hand side is derived from the condensation between 2-methylpropane thioamide 338 and dichloroacetone 339 [100], whilst the other thiazole is obtained from the inexpensive 2,4-thiazolidinedione (341, Scheme 66) [101].


Scheme 66: Thiazole syntheses towards ritonavir.

The dopamine D2-agonist pramipexole (345, Mirapex) consists of a fused bicyclic tetrahydrobenzothiazole motif, which is also prepared by a Hantzsch-type condensation between an α-brominated protected form of 4-aminocyclohexanone 346 and thiourea. Following deprotection, resolution with L-(+)-tartaric acid gives access to the S-enantiomer which undergoes reductive amination and can be isolated as the dihydrochloride salt (Scheme 67) [102].


Scheme 67: Synthesis towards pramipexole.

Alternatively, the thiazole ring can be made in a one pot reaction from the corresponding enamine 350, which is reacted with elemental sulfur to give the α-thioketone 351 (Scheme 68). This in turn can be treated with cyanamide to furnish the racemic thiazole 345 [103]. Resolution with (+)-ditoloyl-D-tartrate allows isolation of the desired S-enantiomer after treatment of the diastereomeric salt with sodium carbonate.


Scheme 68: Alternative route to pramipexole.

Famotidine (352, Pepcidine) is an H2-receptor antagonist similar to cimetidine which inhibits many isoenzymes of the hepatic CYP450 system and has the additional side effect of increasing the amount of gastric bacteria such as nitrate reducing bacteria. The structure of this ulcer therapeutic is very interesting and consists of a thiazole substituted guanidine and a sulfamoyl amidine. Although famotidine is orally administered, its solubility and hence bioavailability under acidic conditions, as found in the stomach, is relatively low. Recent reports have appeared that describe famotidine as a good ligand for various transition metals including copper and cobalt forming tetradentate {N,N,S,N}-coordination spheres as shown by single X-ray analysis [104]. It therefore seems feasible that certain common bioavailable cations might be involved in the absorption and activation of this thiazole containing compound. The synthesis of the thiazole ring [105,106] can be accomplished again by condensation of thiourea with dichloroacetone 340. Alkylation of the isothiourea sulfur with 3-chloropropionitrile (354) and hydrolysis results in the formation of the substitution product 355. Functionalisation of the resulting 2-amino group on the thiazole ring using benzoyl isothiocyanate generates the guanidine precursor 357. A standard sequence of methylation and exchange with ammonia simultaneously cleaves the benzoyl group and unmasks the guanidine unit 358. At the other peripheral of the molecule the nitrile functionality is converted to the imidate and subsequently coupled with sulfamide to yield famotidine (Scheme 69).


Scheme 69: Synthesis of famotidine.

A final example of a thiazole containing drug is given in the novel xanthine oxidase inhibitor febuxostat (359, Uloric) which was approved by the FDA in 2009. This inhibitor works by blocking xanthine oxidase in a non-competitive fashion. Consequently, the amount of the oxidation product uric acid is reduced. Thus it is an efficient treatment for hyperuricemia in gout. In order to prepare febuxostat first a synthesis of the non-commercial 4-isobutoxy-1,3-dicyanobenzene building block (363), has to be conducted. An elegant way of achieving this was shown through the reaction of 4-nitrocyanobenzene (360) with potassium cyanide in dry DMSO followed by quenching with isobutyl bromide under basic conditions (Scheme 70). It is suggested that a Meisenheimer-complex intermediate 361 is initially formed, which after rearomatisation, undergoes nucleophilic aromatic substitution of the nitro group by the DMSO solvent [107]. Upon hydrolysis and O-alkylation the desired 4-isobutoxy-1,3-dicyanobenzene (363) is obtained in good overall yield. Subsequently, the less hindered nitrile is converted to the corresponding thioamide 365 in an intriguing reaction using thioacetamide (364). The thiazole ring is then formed by condensation with chloroacetoacetate 366 followed by ester hydrolysis (Scheme 70).


Scheme 70: Efficient synthesis of the hyperuricemic febuxostat.

Ziprasidone (367, Geodon), is an atypical antipsychotic used to treat schizophrenia as well as mania and related bipolar disorder (Scheme 71). The exact pharmacological effect of ziprasidone is not simple to understand as it affects many subtypes of dopamine, adrenergic and serotonin receptors. However, like many antipsychotic drugs its main therapeutic activity is probably due to its antagonistic action on dopamine receptors. The molecule comprises of a 1,2-benzisothiazole core, which is readily prepared from commercially available benzo[d]isothiazol-3(2H)-one (369), a saccharin derivative [108]. The corresponding chloroimidate 370 formed by treatment of compound 369 with phosphoryl chloride is reacted with excess piperazine to afford intermediate 371 (Route A) [109]. Although this route enabled the synthesis of ziprasidone as its hydrochloride-salt, the nucleophilic aromatic substitution step (370371) was poor and gave only 38% of the desired product [110]. Therefore an improved process was developed involving the oxidative coupling of piperazine with bis(2-cyanophenyl)disulfide (368) at elevated temperatures [109]. Due to the use of DMSO as a co-solvent and oxidant, each equivalent of the disulfide component was then converted into two equivalents of the product making the process more economically efficient. The final union was accomplished using standard Finkelstein alkylation conditions furnishing ziprasidone in 90% yield (Scheme 71) [111].


Scheme 71: Synthesis of ziprasidone.


Mometasone (373, Nasonex) is one of the few examples amongst the top selling pharmaceutical drugs that contains a furan ring. Simple furan structures are not normally viable because of their propensity for rapid metabolism by various oxidation mechanisms. Mometasone is a moderately potent glucocorticoid used for the treatment of inflammatory skin disorders, asthma and allergic rhinitis. Because it is delivered topically or is inhaled, it is not subject to rapid metabolism. Structurally, it consists of a chlorinated dexamethasone core which is esterified with 2-furoic acid at the 17-position (373, Figure 12).


Figure 12: Structure of mometasone.

2-Furoic acid (375) can be obtained via a Cannizzaro-type disproportionation of furfural (374) which is industrially produced from corncobs: Annual production ca. 450,000 tons. Corncobs contain hemicelluloses which degrade to xylose under acidic conditions. Upon strong heating, xylose is converted to furfural, which can be distilled from the biomass (Scheme 72).


Scheme 72: Industrial access to 2-furoic acid present in mometasone.

The furfuryl alcohol (376) obtained in the abovementioned disproportionation (Scheme 72) is also a key starting material for the peptic ulcer therapeutic ranitidine (377, Zantac). In the synthesis of this H2-receptor antagonist, furfuryl alcohol is subjected to a Mannich reaction with paraformaldehyde and dimethylamine hydrochloride. The resultant (5-((dimethylamino)methyl)furan-2-yl)methanol (378) is then treated with cysteamine hydrochloride (380) which leads to replacement of the hydroxyl functionality. Finally, coupling of amine 379 with N-methyl-1-methylthio-2-nitroethenamine (381) furnishes ranitidine (Scheme 73) [112].


Scheme 73: Synthesis of ranitidine from furfuryl alcohol.

In addition, the antibiotic nitrofurantoin (382, Macrobid) used in the treatment of urinary infections is based on a nitrofurfural building block which can be obtained by nitration of furfural (374) [113]. The isolated derivative, acetal 383, can be converted to nitrofurantoin via condensation with aminohydantoin 384 which itself is obtained from cyclisation of semicarbazidoacetic acid under acidic conditions (Scheme 74) [114].


Scheme 74: Synthesis of nitrofurantoin.

Amiodarone (385, Cordarone) is an antiarrhythmic drug containing a benzofuran ring system. It is one of the most effective antiarrhytmic drugs. Although it is considered a class III antiarrhytmic with its mode of action being principally the blocking of potassium channels, it is anticipated that it is also capable of targeting additional sodium and calcium channels. This might explain its general effectiveness, but could also account for its potentially dangerous side effects. The basic benzofuran framework is commonly prepared by alkylation of salicylic aldehyde (386) with chloroacetic acid (387) to give the dihydrobenzofuran carboxylic acid which after intramolecular condensation readily decarboxylates (Scheme 75).


Scheme 75: Synthesis of benzofuran.

A more recent synthesis of amiodarone reports the cyclisation of α-phenoxyhexanal 389 under acidic conditions to yield the substituted benzofuran 390 (Scheme 76). A Friedel–Crafts acylation next introduces the aryl ring at the 3-position. Demethylation, iodination and a final alkylation with a diethylaminoethane fragment yields amiodarone [115-117].


Scheme 76: Synthesis of amiodarone.


Considering the fact that thiophene is a classical bioisostere for a benzene ring it is not surprising that it is encountered in many therapeutically active agents. Amongst the drugs containing a thiophene ring are raloxifene (392, Evista) and olanzapine (399 Zyprexa). The former, which is a benzo[b]thiophene, is widely used as an oral selective estrogen receptor modulator displaying estrogenic actions on bone (prevention of osteoporosis) and anti-estrogenic actions on breast and uterus, especially in the postmenopausal women [118]. The synthesis of the benzo[b]thiophene core 396 was accomplished by condensing 3-mercaptoanisole (393) with 4-methoxyphenacyl bromide (394) firstly under basic conditions to affect the SN2 displacement followed by dehydration with polyphosphoric acid at elevated temperatures (Scheme 77) [119]. Further transformations on this scaffold include the introduction of the carbonyl at the 3-position via a Friedel–Crafts acylation and deprotection, yields raloxifene.


Scheme 77: Synthesis of raloxifene.

A non-classical approach to this same benzo[b]thiophene core 398 is outlined in Scheme 78 [120]. The vinylic sulfoxide 396 undergoes a formal electrophilic cyclisation under the acidic conditions followed by aromatisation to furnish the desired intermediate in high yield.


Scheme 78: Alternative access to the benzo[b]thiophene core of raloxifene.

Another atypical antipsychotic drug which has been long established as a top-selling pharmaceutical is olanzapine (399) which was first introduced to the market by Eli Lilly in 1996. The thiophene unit is synthesised by a multi-component reaction between malononitrile, elemental sulfur and propionaldehyde (400) in the presence of triethylamine. This Gewald-type thiophene synthesis is thought to proceed via an initial Knoevenagel reaction (400402) followed by the addition of the sulfur into the nitrile to form thiocyanate 403 which then ring closes to the aminothiophene product 405. This species is then employed in a nucleophilic aromatic substitution with 2-fluoronitrobenzene (406) to give the coupled product 407. Reduction of the nitro functionality produces the corresponding aniline that readily undergoes ring closure to furnish ultimately the thienobenzodiazepine 408. Substitution of the pendant amine group with excess N-methylpiperazine (409) then affords olanzapine in modest overall yield (Scheme 79) [121].


Scheme 79: Gewald reaction in the synthesis of olanzapine.

In a similar process the malononitrile was replaced with the less toxic methyl cyanoacetate (410) to give the alternative compound 411 (Scheme 80). The previously used nucleophilic substitution was repeated to furnish the methyl ester analogue 412. Then, in order to avoid the use of the strongly acidic reduction and cyclisation conditions employed in Scheme 79 (407408), a milder palladium catalysed hydrogenation was used. Finally, a one pot intramolecular amide formation followed by a TiCl4-mediated reaction to introduce the amidine function yields olanzapine (Scheme 80) [122].


Scheme 80: Alternative synthesis of olanzapine.

Three additional thiophene-containing drugs are duloxetine (414, Cymbalta), tiotropium (415, Spiriva) and Cosopt [dorzolamide (416) (Figure 13) and its second active ingredient timolol (see also Scheme 84)]. However, the syntheses of all three compounds use simple thiophene starting materials, viz. the carboxylic acid 417, for duloxetine [123], or a Grignard reagent (418) for tiotropium [124] and thiophene-2-thiol (419) for dorzolamide [125].


Figure 13: Access to simple thiophene-containing drugs.

One of the most successful platelet aggregation inhibitors currently on the market is clopidogrel (420, Plavix) which is a chiral tetrahydrothieno[3,2-c]pyridine derivative (Scheme 81). In the favoured synthetic route this tricyclic motif is prepared by a nucleophilic substitution of α-bromo 2-chlorophenyl acetonitrile (421) with a secondary amine 422. Subsequent hydrolysis of the secondary nitrile under phase transfer conditions delivers the free acid which is converted to the methyl ester 424. In order to obtain the desired S-enantiomer, a classical resolution with ca. 0.5 equiv of L-camphorsulfonic acid (L-CSA) in toluene is used. The desired enantiomer 420 is collected as a crystalline salt in greater than 98% ee and 88% of the expected yield (Scheme 81) [126]. The remaining material can be easily epimerised under mildly basic conditions.


Scheme 81: Synthesis of clopidogrel.

Although the tetrahydrothieno[3,2-c]pyridine structure 422 is now readily available on a large scale from various commercial sources, it was originally synthesised in a variety of ways. The most straightforward route was from thiophene-2-carbaldehyde (425) which was subjected to a Henry reaction with nitromethane. Reduction of the nitro olefin function to the corresponding alkylamine followed by reaction with formaldehyde gave the corresponding imine 426 [127]. Treatment of the latter with hydrochloric acid initiates a Pictet–Spengler reaction to furnish the desired heterocycle in high overall yield (Scheme 82).


Scheme 82: Pictet–Spengler reaction in the preparation of tetrahydrothieno[3,2-c]pyridine (422).

This key compound can also be accessed by assembling the thiophene ring. In this scenario N-protected 4-piperidone 427 is subjected to Vilsmeier conditions to produce the reactive chloroaldehyde species 428 which, upon treatment with ethyl mercaptoacetate (429), cyclises to the heterocyclic structure although in only low isolated yield. Simple base hydrolysis of the ester followed by decarboxylation generates the desired product (Scheme 83) [128].


Scheme 83: Alternative synthesis of key intermediate 422.


Cosopt, an ophthalmic medication, consists of the two active ingredients dorzolamide (416; Figure 13), a carboanhydrase inhibitor used as an anti-glaucoma agent, and timolol (432; Figure 14) a β-adrenergic receptor blocker used to lower intra-ocular pressure by reduction of aqueous humour production. In a recent report an X-ray co-crystal structure of timolol within the β2-adrenergic receptor was disclosed [129]. An overlay of this structure with a previous one showing the position of carazolol (433), an analogue of the previously mentioned carvedilol (136) β-blocker, shows the binding of these molecules (Figure 14). Additionally, this data nicely exemplifies the stronger binding of timolol, as its morpholine group is involved in an extra hydrogen-bonding network with nearby amino acids (Asn, Tyr, Ser) and the thiadiazole motif itself protrudes deeper into the actual binding pocket when compared with the carbazole system of carazolol which results in stronger interactions.


Figure 14: Co-crystal structures of timolol (left) and carazolol (right) in the β-adrenergic receptor.

Whilst the synthesis of the thiophene-containing component (dorzolamide) of Cosopt starts from 2-mercaptothiophene and elaborates the thienothiopyran motif in a linear multi-step fashion, the thiadiazole ring of timolol is prepared from an acyclic precursor (Scheme 84). The active pharmaceutical ingredient (API) timolol is prepared via a biocatalytic asymmetric reaction which permits selective access to both enantiomers [130]. Starting from 3,4-dichloro-1,2,5-thiadiazole (435), which can be prepared from cyanogen (434) and sulfur dichloride [131], the two chlorides are differentiated by sequential substitution reactions using morpholine and sodium hydroxide. The resulting hydroxyl in compound 436 is alkylated with dichloroacetone to yield a carbonyl compound 437 susceptible to enzymatic reduction with baker’s yeast. The levorotatory enantiomer thus obtained can be subjected to Mitsunobu conditions with benzoic acid as the nucleophile and leads to clean inversion of the stereocentre which thus gives access to the other enantiomer of timolol. Under basic conditions the chlorohydrin 438 can be converted to the corresponding epoxide which can be ring opened by tert-butyl amine to furnish timolol (Scheme 84).


Scheme 84: Synthesis of timolol.

A related heterocyclic structure can be found in the skeletal muscle relaxant tizanidine (440, Zanaflex). This substituted 2,1,3-benzothiadiazole 442 can be prepared by the reaction of an aromatic diamine 441 on heating with thionyl chloride in the presence of DMF. Selective nitration followed by an iron-mediated reduction affords the corresponding aniline 443 which partakes in a nucleophilic substitution of 2-chloro-3,4-dihydroimidazole (generated in situ from the reaction of the urea 444 and phosphoryl chloride). Removal of the acetate group under basic conditions furnishes tizanidine (Scheme 85) [132].


Scheme 85: Synthesis of tizanidine 440.

Isoxazoles and benzisoxazole

The isoxazole ring is a common heterocyclic motif represented by several of the top-selling small molecule pharmaceuticals. This ring structure is often encountered as a surrogate of other nitrogen containing heterocycles such as pyrazoles, pyridines or pyrimidines [133]. Two specific drugs containing this structure are leflunomide (446, Arava) and sulfamethoxazole (447, Bactrim).

Leflunomide is a pyrimidine synthase inhibitor of the DMARD-type (disease-modifying anti-rheumatic drug) marketed by Sanofi-Aventis. Unlike NSAIDs, which only deal with symptoms of rheumatoid arthritis, DMARDs target the cause of it. DMARDs are not necessarily structurally or mechanistically related. The effect of leflunomide is possibly due to its regulation of the immune system via affecting lymphocytes. Its synthesis [134] is relatively straightforward starting with a Knoevenagel condensation of ethyl acetoacetate (39) and triethyl orthoformate in the presence of acetic anhydride. The resulting ethyl ethoxymethylene acetoacetate (448) is next condensed with hydroxylamine hydrate in methanol to yield ethyl 5-methylisoxazole-4-carboxylate (449). The ethyl ester is hydrolysed under acidic conditions and the carboxylic acid activated with thionyl chloride in DMF for amide formation with 4-trifluoromethylaniline (450) (Scheme 86).


Scheme 86: Synthesis of leflunomide.

A related condensation between (E)-4-(dimethylamino)but-3-en-2-one (451) and hydroxylamine is used in the synthesis of bactriostatic antibiotic sulfamethoxazole (447) to yield the equivalent 5-methylisoxazole (452) (Scheme 87). This basic unit is then nitrated with a mixture of ammonium nitrate in trifluoroacetic anhydride 240, which is presumed to form the active trifluoroacetyl nitrate, and converted to the 3-amino-5-methylisoxazole (453) in a aluminium-amalgam mediated reduction [135,136]. Sulfonamide formation with the sulfonyl chloride 454 yields the antibiotic agent 447 (Scheme 87).


Scheme 87: Synthesis of sulfamethoxazole.

The most prescribed therapeutic for schizophrenia is the benzisoxazole containing antipsychotic risperidone (455, Risperdal). For this molecule the benzisoxazole ring is formed via an intramolecular nucleophilic aromatic substitution between an in situ generated oxime 459 and the adjacent aromatic ring [137]. The precursor carbonyl derivative 458 arises from a Friedel–Crafts acylation of the difluoroaromatic 457 (the acetate N-protecting group is presumably lost in the work up). Finally, alkylation of the piperidine ring under Finkelstein conditions is used to complete the synthesis of risperidone (Scheme 88).


Scheme 88: Synthesis of risperidone.


Having collected data with respect to many different reported syntheses of drugs containing heteroaromatic five-membered rings, a number of observations can be drawn. For instance, it was established that the most common transformations used are indeed condensations and nucleophilic substitution reactions (Figure 15) [138,139]. This can be rationalised by considering that only small molecular weight by-products such as water or hydrogen chloride/bromide are generated, which are benign and can be easily removed. Other well represented transformations include reductions, amide and ester formations, rearrangements and saponifications, which can be performed in an atom-economic manner based on numerous well established protocols. On the other hand, other robust transformations such as oxidations, nucleophilic aromatic substitutions, olefinations, cycloadditions and metal-mediated transformations appear to be rarely used. The reasons for this might be the need for stoichiometric reagents leading to large amounts of waste as well as potential heavy metal contamination. In addition, these reactions are usually accompanied by the release of heat due to exothermic reaction profiles which might result in difficult to control and therefore undesired chemical processes.


Figure 15: Relative abundance of selected transformations.

An additional comment should be made about the time frame of new reaction uptake within the process environment. For certain reaction types such as metathesis and C–H activation, which obviously offer significant synthetic potential, it could be argued that the length of time required for these reactions to evolve from research tools to production processes are outwith the pipeline development times of the drugs under discussion. A significant body of the literature representing the synthesis of these drugs date back many years to origins in the late seventies and early eighties. Consequently, it is probably not unexpected to see the absence of many of the ‘newer’ chemical methodologies.

Interestingly, the above-mentioned classes of chemical reactions are most widely applied to a limited number of heterocyclic cores with indoles, triazoles and benzimidazoles being the most prominent examples to date (Figure 16). It can be postulated that this is likely due to two possible factors; 1) the utilisation of so-called ‘me-too drug’ approaches by pharmaceutical companies or 2) the fact that these are privileged structures which avoid the limitations of many other aromatic heterocycles in biological systems such as toxicity. However, the more recent trend seems to indicate a move towards more diverse scaffolds. This might be ascribed to the massive efforts of the pharmaceutical industry to find new drug classes, but could also be an indication of the patenting approaches used to protect more comprehensively these new developments. Furthermore, this move towards novel heterocyclic structures also allows for more flexible substitution patterns permitting extensive SAR studies through efficient high throughput screenings commonly used today.


Figure 16: The abundance of heterocycles within top 200 drugs (5-membered rings).

One constant in all the drug syntheses is the shortness of the reported routes, which typically do not exceed 6–8 steps. Furthermore, chiral centres are still less well represented in drugs unless they can be sourced cheaply from the chiral pool or accessed from commercial suppliers specialised in asymmetric synthesis, for instance, hydrogenations or enzymatic transformations/resolutions. It is predicted [140] that the number of future drugs bearing chirality will increase due to more reliable and affordable catalytic asymmetric transformations [141].

Based on the material presented in this review it can be concluded that most of the reported routes towards well established drugs are based on conventional transformations to furnish the desired compound quickly. However, with increasing competition between the pharmaceutical companies and additional pressures from regulatory/government authorities, chemical producers will need to adopt improved processing techniques that encompass a reduced environmental footprint and deliver the APIs at significantly reduced cost. In order to achieve the necessary productivity gains future chemistry programmes will have to employ a wider range of synthetic transformations targeted at delivering molecules covering an expanded area of chemical space. This will not be solely achieved by minor improvements in the efficiency of individual chemical reactions but will need the industry to integrate actively all the new tools and enabling technologies within their research and manufacturing efforts [142].


We gratefully acknowledge financial support from the Cambridge European Trust and the Ralph Raphael Studentship Award (to MB), the EPSRC (to NN), the Royal Society (to IRB) and the BP endowment (to SVL).


  1. MIDAS World Review (TM), January 2009 - December 2009, IMS Health Incorporated.
    Return to citation in text: [1]
  2. McGrath, N. A.; Brichacek, M.; Njardarson, J. T. J. Chem. Educ. 2010, 87, 1348–1349. doi:10.1021/ed1003806
    Return to citation in text: [1]
  3. Roth, B. D.; Blankley, C. J.; Chucholowski, A. W.; Ferguson, E.; Hoefle, M. L.; Ortwine, D. F.; Newton, R. S.; Sekerke, C. S.; Sliskovic, D. R.; Wilson, M. J. Med. Chem. 1991, 34, 357–366. doi:10.1021/jm00105a056
    Return to citation in text: [1]
  4. Roth, B. D. Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one Inhibitors of Cholesterol Synthesis. U.S. Patent 4,681,893, July 21, 1987.
    Return to citation in text: [1]
  5. Sagyam, R. R.; Padi, P. R.; Ghanta, M. R.; Vurimidi, H. J. Heterocycl. Chem. 2007, 44, 923–926. doi:10.1002/jhet.5570440429
    Return to citation in text: [1]
  6. Butler, D. E.; Deering, C. F.; Millar, A.; Nanninga, T. N.; Roth, B. D. Improved Process for Trans-6-[2-(substituted-pyrrole-1-yl)alkyl]pyran-2-one Inhibitors of Cholesterol Synthesis. WO Patent 89/07598, Aug 24, 1989.
    Return to citation in text: [1]
  7. Butler, D. E.; Le, T. V.; Millar, A.; Nanninga, T. N. Process for the Synthesis of (5R)-1,1-Dimethylethyl-6-cyano-5-hydroxy-3-oxohexanoate. U.S. Patent 5,155,251, Oct 13, 1992.
    Return to citation in text: [1]
  8. Gajiwala, K. S.; Wu, J. C.; Christensen, J.; Deshmukh, G. D.; Diehl, W.; DiNitto, J. P.; English, J. M.; Greig, M. J.; He, Y.-A.; Jacques, S. L.; Lunney, E. A.; McTigue, M.; Molina, D.; Quenzer, T.; Wells, P. A.; Yu, X.; Zhang, Y.; Zou, A.; Emmett, M. R.; Marshall, A. G.; Zhang, H.-M.; Demetri, G. D. Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 1542–1547. doi:10.1073/pnas.0812413106
    Return to citation in text: [1]
  9. Lednicer, D. Indolones. In The Organic Chemistry of Drug Synthesis, Vol. 7; Wiley-Interscience: Hoboken, New Jersey, 2008; pp 148–152.
    Return to citation in text: [1]
  10. Vaidyanathan, R. The SUTENT® Story. In Process Chemistry in the Pharmaceutical Industry; Gadamasetti, K.; Braish, T., Eds.; Taylor & Francis: Boca Raton, Florida, 2008; Vol. 2, pp 49–64.
    Return to citation in text: [1]
  11. Pete, B.; Bitter, I.; Szántay, C., Jr.; Schön, I.; Töke, L. Heterocycles 1998, 48, 1139–1149. doi:10.3987/COM-97-8087
    Return to citation in text: [1]
  12. Oxford, A. W. Indole Derivative. U.S. Patent 5,037,845, Aug 6, 1991.
    Return to citation in text: [1]
  13. Japp, F. R.; Klingemann, F. Chem. Ber. 1887, 20, 2942–2944. doi:10.1002/cber.188702002165
    Return to citation in text: [1]
  14. Pete, B.; Bitter, I.; Harsányi, K.; Töke, L. Heterocycles 2000, 53, 665–673. doi:10.3987/COM-99-8815
    Return to citation in text: [1]
  15. Kim, D.-W.; Ko, Y. K.; Kim, S. H. Synthesis 1992, 12, 1203–1204. doi:10.1055/s-1992-26333
    Return to citation in text: [1]
  16. Albinson, F. D.; MacKinnon, J. W. M.; Crookes, D. L. Preparation of Indole Derivatives. U.S. Patent 5,103,020, April 7, 1992.
    Return to citation in text: [1]
  17. Zhou, G.; Ting, P.; Aslanian, R.; Piwinski, J. J. Org. Lett. 2008, 10, 2517–2520. doi:10.1021/ol800785g
    Return to citation in text: [1]
  18. Blatcher, P.; Carter, M.; Hornby, R.; Owen, M. Process for the Preparation of N-Methyl-3-(1-methyl-4-piperidinyl)-4-indole-5-ethanesulphonamide. WO Patent 95/091166, April 6, 1995.
    Return to citation in text: [1]
  19. Buckingham, J.; Glen, R. C.; Hill, A. P.; Hyde, R. M.; Martin, G. R.; Robertson, A. D.; Salmon, J. A.; Woollard, P. M. J. Med. Chem. 1995, 38, 3566–3580. doi:10.1021/jm00018a016
    Return to citation in text: [1]
  20. Voslar, M.; Zatopkova, M.; Ridvan, L.; Pekarek, T. A. Method for the Preparation of Zolmitriptan. WO Patent 2008/104134, Sept 4, 2008.
    Return to citation in text: [1]
  21. Baker, R.; Matassa, V. G.; Street, L. J. Triazole Containing Indole Derivatives. U.S. Patent 5,298,520, March 29, 1994.
    Return to citation in text: [1]
  22. Street, L. J.; Baker, R.; Davey, W. B.; Guiblin, A. R.; Jelley, R. A.; Reeve, A. J.; Routledge, H.; Sternfeld, F.; Watt, A. P. J. Med. Chem. 1995, 38, 1799–1810. doi:10.1021/jm00010a025
    Return to citation in text: [1]
  23. Koilpillai, J. P.; Subramanian, M.; Mallela, U.; Boddu, V. B.; Dandala, R.; Meenakshisunderam, S. An Improved Process for the Preparation of Rizatriptan. WO Patent 2008/075163, June 26, 2008.
    Return to citation in text: [1]
  24. Larock, R. C.; Yum, E. K.; Refvik, M. D. J. Org. Chem. 1998, 63, 7652–7662. doi:10.1021/jo9803277
    Return to citation in text: [1]
  25. Chen, C.-y.; Lieberman, D. R.; Larsen, R. D.; Reamer, R. A.; Verhoeven, T. R.; Reider, P. J.; Cottrell, I. F.; Houghton, P. G. Tetrahedron Lett. 1994, 35, 6981–6984. doi:10.1016/0040-4039(94)88204-5
    Return to citation in text: [1]
  26. Muddasani, P. R.; Hanumara, S. R.; Kagitha, R.; Nannapaneni, V. C. Improved Process for the Preparation of Rizatriptan Benzoate. WO Patent 2006/137083, Dec 28, 2006.
    Return to citation in text: [1]
  27. Chen, C. Y.; Larsen, R. D.; Verhoeven, T. R. Palladium Catalyzed Ring Closure of Triazolyl Tryptamine. WO Patent 95/32197, Nov 30, 1995.
    Return to citation in text: [1]
  28. Macor, J. E.; Wythes, M. J. Indole Derivatives. U.S. Patent 5,545,644, Aug 13, 1996.
    Return to citation in text: [1]
  29. Perkins, J. F. Process for the Preparation of 3-Acylindoles. Eur. Patent 1088817A2, April 4, 2001.
    Return to citation in text: [1]
  30. Ashcroft, C. P. Modified Fischer Indole Synthesis for Eletriptan. WO Patent 2005/103035, Nov 3, 2005.
    Return to citation in text: [1]
  31. Bischler, A. Chem. Ber. 1892, 25, 2860–2879. doi:10.1002/cber.189202502123
    Return to citation in text: [1]
  32. Sridharan, V.; Perumal, S.; Avendaño, C.; Menéndez, J. C. Synlett 2006, 2006, 91–95. doi:10.1055/s-2005-922760
    Return to citation in text: [1]
  33. Repič, O.; Prasad, K.; Lee, G. T. Org. Process Res. Dev. 2001, 5, 519–527. doi:10.1021/op0100450
    Return to citation in text: [1]
  34. Walkup, R. E.; Linder, J. Tetrahedron Lett. 1985, 26, 2155–2158. doi:10.1016/S0040-4039(00)98949-4
    Return to citation in text: [1]
  35. Godfrey, N.; Coates, I. H.; Bell, J. A.; Humber, D. C.; Ewan, G. B. Process for Preparing N-Heterocyclic Compounds. U.S. Patent 4,957,609, Sept 18, 1990.
    Return to citation in text: [1]
  36. Iida, H.; Yuasa, Y.; Kibayashi, C. J. Org. Chem. 1980, 45, 2938–2942. doi:10.1021/jo01303a003
    Return to citation in text: [1]
  37. Oxford, A. W.; Eldred, C. D.; Coates, I. H.; Bell, J. A.; Humber, D. C.; Ewan, G. B. Process for Preparing Tetrahydrocarbazolones. U.S. Patent 4,739,072, April 19, 1988.
    Return to citation in text: [1]
  38. Daugan, A. C.-M. Tetracyclic Derivatives; Process of Preparation and Use. U.S. Patent 5,859,006, Jan 12, 1999.
    Return to citation in text: [1] [2]
  39. Daugan, A. C.-M. Tetracyclic Derivatives, Process of Preparation and Use. U.S. Patent 6,025,494, Feb 15, 2000.
    Return to citation in text: [1]
  40. Shi, X.-X.; Liu, S.-L.; Xu, W.; Xu, Y.-L. Tetrahedron: Asymmetry 2008, 19, 435–442. doi:10.1016/j.tetasy.2007.12.017
    Return to citation in text: [1]
  41. Yue, T.-L.; Cheng, H.-Y.; Lysko, P. G.; McKenna, P. J.; Feuerstein, R.; Gu, J.-L.; Lysko, K. A.; Davis, L. L.; Feuerstein, G. J. Pharmacol. Exp. Ther. 1992, 263, 92–98.
    Return to citation in text: [1]
  42. Lauer, K.; Kiegel, E. Process for the Preparation of 4-Hydroxycarbazole. U.S. Patent 4,273,711, June 16, 1981.
    Return to citation in text: [1] [2]
  43. Huang, S.; Yu, H.; Sun, X.; Gao, W. Zhongguo Yaowu Huaxue Zazhi 2000, 10, 293–295.
    Return to citation in text: [1]
  44. Demerson, C. A.; Humber, L. G.; Dobson, T.; Jirkovsky, I. L. Certain pyrano[3,4-B]indoles and thiopyrano[3,4-B]indoles. U.S.Patent 3,393,178, Feb 17, 1976.
    Return to citation in text: [1]
  45. Demerson, C. A.; Humber, L. G. Process for Preparing 1,8-Diethyl-1,3,4,9-tetrahydropyrano(3,4-b)-indole-1-acetic acid, Etodolac. U.S. Patent 4,585,877, April 29, 1986.
    Return to citation in text: [1]
  46. Vincenzo, G.; Franco, P. 3-(2-Trialkylsilyloxy)ethyl-7-ethyl-1H-indoles and Method for their Preparation. U.S. Patent 5,599,946, Feb 4, 1997.
    Return to citation in text: [1]
  47. Woods, M.; Dyer, U. C.; Andrews, J. F.; Morfitt, C. N.; Valentine, R.; Sanderson, J. Org. Process Res. Dev. 2000, 4, 418–426. doi:10.1021/op000014p
    Return to citation in text: [1]
  48. De Gasparo, M.; Catt, K. J.; Inagami, T.; Wright, J. W.; Unger, T. Pharmacol. Rev. 2000, 52, 415–472.
    Return to citation in text: [1]
  49. Bühlmayer, P.; Furet, P.; Criscione, L.; de Gasparo, M.; Whitebread, S.; Schmidlin, T.; Lattmann, R.; Wood, J. Bioorg. Med. Chem. Lett. 1994, 4, 29–34. doi:10.1016/S0960-894X(01)81117-3
    Return to citation in text: [1] [2]
  50. Shi, Y.-J.; Frey, L. F.; Tschaen, D. M.; Verhoeven, T. R. Synth. Commun. 1993, 23, 2623–2630. doi:10.1080/00397919308012598
    Return to citation in text: [1]
  51. Griffiths, G. J.; Hauck, M. B.; Imwinkelried, R.; Kohr, J.; Roten, C. A.; Stucky, G. C.; Gosteli, J. J. Org. Chem. 1999, 64, 8084–8089. doi:10.1021/jo9824910
    Return to citation in text: [1] [2]
  52. Zhong, Y.-L.; Lee, J.; Reamer, R. A.; Askin, D. Org. Lett. 2004, 6, 929–931. doi:10.1021/ol036423y
    Return to citation in text: [1]
  53. Yanagisawa, H.; Fujimoto, K.; Amemiya, Y.; Shimoji, Y.; Kanazaki, T.; Koike, H.; Sada, T. Angiotensin II Antagonist 1-Biphenylmethylimidazole Compounds and their Therapeutic Use. U.S. Patent 5,616,599, April 1, 1997.
    Return to citation in text: [1]
  54. Yanagisawa, H.; Amemiya, Y.; Kanazaki, T.; Shimoji, Y.; Fujimoto, K.; Kitahara, Y.; Sada, T.; Mizuno, M.; Ikeda, M.; Miyamoto, S.; Furukawa, Y.; Koike, H. J. Med. Chem. 1996, 39, 323–338. doi:10.1021/jm950450f
    Return to citation in text: [1]
  55. Tyers, M. B.; Coates, I. H.; Humber, D. C.; Ewan, G. B.; Bell, J. A. Method for Treating Nausea and Vomiting. U.S. Patent 4,753,789, June 28, 1988.
    Return to citation in text: [1]
  56. Gitis, K. M.; Raevskaya, N. I.; Isagulyants, G. V. Russ. Chem. Bull. 1992, 41, 1551–1554. doi:10.1007/BF00863570
    Return to citation in text: [1]
  57. Elz, S.; Heil, W. L. Bioorg. Med. Chem. Lett. 1995, 5, 667–672. doi:10.1016/0960-894X(95)00092-8
    Return to citation in text: [1]
  58. Uchida, M.; Morita, S.; Chihiro, M.; Kanbe, T.; Yamasaki, K.; Yabuuchi, Y.; Nakagawa, K. Chem. Pharm. Bull. 1989, 37, 1517–1523.
    Return to citation in text: [1]
  59. Lindberg, P. L.; Von Unge, S. Compositions. U.S. Patent 5,714,504, Feb 3, 1998.
    Return to citation in text: [1]
  60. Cotton, H.; Kronström, A.; Mattson, A.; Möller, E. Novel Form of S-Omeprazole. WO Patent 98/54171, Dec 3, 1998.
    Return to citation in text: [1]
  61. Rainer, G.; Riedel, R.; Senn-Biffinger, J.; Klemm, K.; Schaefer, H.; Figaia, V. Fluoroalkoxysubstituted Pyridylmethylthio-(or Sulfinyl)-benzimidazoles. Eur. Patent 134400B1, March 24, 1993.
    Return to citation in text: [1]
  62. Hashimoto, H.; Hanaoka, T.; Kato, M. Production Method of Aminobenzene Compound. Eur. Patent 0881212B1, Dec 2, 1998.
    Return to citation in text: [1]
  63. Snieckus, V. Chem. Rev. 1990, 90, 879–933. doi:10.1021/cr00104a001
    Return to citation in text: [1]
  64. Porcs-Makkay, M.; Mezei, T.; Simig, G. Org. Process Res. Dev. 2007, 11, 490–493. doi:10.1021/op700041z
    Return to citation in text: [1]
  65. Ries, U. J.; Mihm, G.; Narr, B.; Hasselbach, K. M.; Wittneben, H.; Entzeroth, M.; van Meel, J. C. A.; Wienen, W.; Hauel, N. H. J. Med. Chem. 1993, 36, 4040–4051. doi:10.1021/jm00077a007
    Return to citation in text: [1] [2]
  66. Reddy, K. S.; Srinivasan, N.; Reddy, C. R.; Kolla, N.; Anjaneyulu, Y.; Venkatraman, S.; Bhattacharya, A.; Mathad, V. T. Org. Process Res. Dev. 2007, 11, 81–85. doi:10.1021/op060200g
    Return to citation in text: [1]
  67. Rossey, G.; Long, D. Process for the Preparation of Imidazopyridines. U.S. Patent 4,794,185, Dec 27, 1988.
    Return to citation in text: [1]
  68. George, P.; Rossey, G.; Depoortere, H.; Mompon, B.; Allen, J.; Wick, A. Farmaco 1991, 46, 277–288.
    Return to citation in text: [1]
  69. Chernyak, N.; Gevorgyan, V. Angew. Chem., Int. Ed. 2010, 49, 2743–2746. doi:10.1002/anie.200907291
    Return to citation in text: [1]
  70. Zhu, J.; Song, X.; Lin, H.-P.; Young, D. C.; Yan, S.; Marquez, V. E.; Chen, C.-S. J. Natl. Cancer Inst. 2002, 94, 1745–1757. doi:10.1093/jnci/94.23.1745
    Return to citation in text: [1]
  71. Rimon, G.; Sidhu, R. S.; Lauver, D. A.; Lee, J. Y.; Sharma, N. P.; Yuan, C.; Frieler, R. A.; Trievel, R. C.; Lucchesi, B. R.; Smith, W. L. Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 28–33. doi:10.1073/pnas.0909765106
    Return to citation in text: [1]
  72. Penning, T. D.; Talley, J. J.; Bertenshaw, S. R.; Carter, J. S.; Collins, P. W.; Docter, S.; Graneto, M. J.; Lee, L. F.; Malecha, J. W.; Miyashiro, J. M.; Rogers, R. S.; Rogier, D. J.; Yu, S. S.; Anderson, G. D.; Burton, E. G.; Cogburn, J. N.; Gregory, S. A.; Koboldt, C. M.; Perkins, W. E.; Seibert, K.; Veenhuizen, A. W.; Zhang, Y. Y.; Isakson, P. C. J. Med. Chem. 1997, 40, 1347–1365. doi:10.1021/jm960803q
    Return to citation in text: [1]
  73. Talley, J. J.; Penning, T. D.; Collins, P. W.; Rogier, D. J., Jr.; Malecha, J. W.; Miyashiro, J. M.; Bertenshaw, S. R.; Khanna, I. K.; Granets, M. J.; Rogers, R. S.; Carters, J. S.; Docter, S. H. Substituted Pyrazolylbenzenesulfonamides for the Treatment of Inflammation. WO Patent 95/15316, June 8, 1995.
    Return to citation in text: [1]
  74. Reddy, M. V. R.; Bell, S. C. Processes for the Preparation of 1,5-diaryl-3-substituted Pyrazoles. WO Patent 03/024958, March 27, 2003.
    Return to citation in text: [1]
  75. Oh, L. M. Tetrahedron Lett. 2006, 47, 7943–7946. doi:10.1016/j.tetlet.2006.08.138
    Return to citation in text: [1]
  76. Pandite, A. N.; Whitehead, B. F.; Ho, P. T. C.; Suttle, A. B. Cancer Treatment Method. WO Patent 2007/064753, June 7, 2007.
    Return to citation in text: [1]
  77. Harris, P. A.; Boloor, A.; Cheung, M.; Kumar, R.; Crosby, R. M.; Davis-Ward, R. G.; Epperly, A. H.; Hinkle, K. W.; Hunter, R. N., III; Johnson, J. H.; Knick, V. B.; Laudeman, C. P.; Luttrell, D. K.; Mook, R. A.; Nolte, R. T.; Rudolph, S. K.; Szewczyk, J. R.; Truesdale, A. T.; Veal, J. M.; Wang, L.; Stafford, J. A. J. Med. Chem. 2008, 51, 4632–4640. doi:10.1021/jm800566m
    Return to citation in text: [1]
  78. Ray, P. C.; Bandari, M.; Qadeeruddin, M.; Manjaneyulu, G. S. Process for the Large Scale Production of Rizatriptan Benzoate. WO Patent 2007/054979, May 18, 2007.
    Return to citation in text: [1]
  79. Solanki, K. S.; Pal, G.; Haider, H.; Singh, M.; Kothari, J. S.; Agarwal, V. K. A Process for the Preparation of Pure Anastrozole. WO Patent 2007/054963, May 18, 2007.
    Return to citation in text: [1] [2]
  80. Gaitonde, A.; Vaidaya, C.; Pawar, S. R. Process for the Preparation of Anastrozole. WO Patent 2006/000836, Jan 5, 2006.
    Return to citation in text: [1]
  81. Grundmann, C.; Ratz, R. J. Org. Chem. 1956, 21, 1037–1038. doi:10.1021/jo01115a610
    Return to citation in text: [1]
  82. Martin, P.; Berens, U.; Boudier, A.; Dosenbach, O. Synthesis Methods and Intermediates for the Manufacture of Rizatriptan. WO Patent 2005/075422, Aug 18, 2005.
    Return to citation in text: [1]
  83. Kim, D.; Wang, L.; Beconi, M.; Eiermann, G. J.; Fisher, M. H.; He, H.; Hickey, G. J.; Kowalchick, J. E.; Leiting, B.; Lyons, K.; Marsilio, F.; McCann, M. E.; Patel, R. A.; Petrov, A.; Scapin, G.; Patel, S. B.; Roy, R. S.; Wu, J. K.; Wyvratt, M. J.; Zhang, B. B.; Zhu, L.; Thornberry, N. A.; Weber, A. E. J. Med. Chem. 2005, 48, 141–151. doi:10.1021/jm0493156
    Return to citation in text: [1]
  84. Hansen, K. B.; Balsells, J.; Dreher, S.; Hsiao, Y.; Kubryk, M.; Palucki, M.; Rivera, N.; Steinhuebel, D.; Armstrong, J. D., III; Askin, D.; Grabowski, E. J. J. Org. Process Res. Dev. 2005, 9, 634–639. doi:10.1021/op0500786
    Return to citation in text: [1]
  85. Balsells, J.; DiMichele, L.; Liu, J.; Kubryk, M.; Hansen, K.; Armstrong, J. D., III. Org. Lett. 2005, 7, 1039–1042. doi:10.1021/ol0474406
    Return to citation in text: [1]
  86. Haycock-Lewandowski, S. J.; Wilder, A.; Åhman, J. Org. Process Res. Dev. 2008, 12, 1094–1103. doi:10.1021/op8000614
    Return to citation in text: [1]
  87. Hester, J. P., Jr.; Rudzik, A. D.; Kamdar, B. V. J. Med. Chem. 1971, 14, 1078–1081. doi:10.1021/jm00293a015
    Return to citation in text: [1]
  88. Sternbach, L. H.; Fryer, R. I.; Metlesics, W.; Reeder, E.; Sach, G.; Saucy, G.; Stempel, A. J. Org. Chem. 1962, 27, 3788–3796. doi:10.1021/jo01058a010
    Return to citation in text: [1]
  89. Fustero, S.; González, J.; del Pozo, C. Molecules 2006, 11, 583–588. doi:10.3390/11080583
    Return to citation in text: [1]
  90. Heeres, J.; Backx, L. J. J.; Van Cutsem, J. J. Med. Chem. 1984, 27, 894–900. doi:10.1021/jm00373a015
    Return to citation in text: [1]
  91. Portmann, R. Process for preparing 1-substituted 4-cyano-1,2,3-triazoles. WO Patent 98/02423, Jan 22, 1998.
    Return to citation in text: [1]
  92. Portmann, R.; Hofmeier, C.; Burkhard, A.; Scherrer, W.; Szelagiewicz, M. Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic. US Patent 6,740,669 B1, May 25, 2004.
    Return to citation in text: [1]
  93. Hudd, W. H.; Stevens, E. P. Tetrahedron Lett. 2010, 51, 3229–3231. doi:10.1016/j.tetlet.2010.04.060
    Return to citation in text: [1]
  94. Wang, Y.; Li, Y.; Li, Y.; Zheng, G.; Li, Y. Method for the Production of Losartan. WO Patent 2006/081807, Aug 10, 2006.
    Return to citation in text: [1]
  95. Mendelovici, M.; Finkelstein, N.; Pilarski, G. Process for Preparing Cilostazol. U.S. Patent 6,515,128, Feb 4, 2003.
    Return to citation in text: [1]
  96. Nishi, T.; Nakagawa, K. Tetrazolylalkoxycarbostyryl Derivatives and Pharmaceutical Compositions Containing them. U.S. Patent 4,277,479, July 7, 1981.
    Return to citation in text: [1]
  97. Guay, D. R. P. Clin. Ther. 2002, 24, 473–489. doi:10.1016/S0149-2918(02)85125-6
    Return to citation in text: [1]
  98. Mooney, M. T.; Deguchi, S.; Tada, T.; Fujioka, M.; Okamoto, Y.; Yasuda, T. Chem. Pharm. Bull. 1995, 43, 374–377.
    Return to citation in text: [1]
  99. González, M.; Rodriguez, Z.; Tolón, B.; Rodriguez, J. C.; Veléz, H.; Valdez, B.; Lopéz, M. A.; Fini, A. Farmaco 2003, 58, 409–418. doi:10.1016/S0014-827X(03)00063-6
    Return to citation in text: [1]
  100. Kempf, D. J.; Marsh, K. C.; Denissen, J. F.; McDonald, E.; Vasavanonda, S.; Flentge, C. A.; Green, B. E.; Fino, L.; Park, C. H.; Kong, X. P. Proc. Natl. Acad. Sci. U. S. A. 1995, 92, 2484–2488. doi:10.1073/pnas.92.7.2484
    Return to citation in text: [1]
  101. Kerdesky, F. A. J.; Seif, L. S. Synth. Commun. 1995, 25, 2639–2645. doi:10.1080/00397919508011810
    Return to citation in text: [1]
  102. Schneider, C.; Griss, G.; Hurnaus, R.; Kobinger, W.; Pichler, L.; Bauer, R.; Mierau, J.; Hinzen, D.; Schingnitz, G. Tetrahydrobenzothiazoles, their Production and Use as Intermediates and Pharmaceuticals. Eur. Patent 186087B1, July 2, 1986.
    Return to citation in text: [1]
  103. Martin Juarez, J.; Silva Guisasola, L. O. Method for the Resolution of 2-Amino-6-propylamino-4,5,6,7-tetrahydrobenzothiazole and Intermediate Compounds. WO Patent 2006/120268, Nov 16, 2006.
    Return to citation in text: [1]
  104. Miodragović, D. U.; Bogdanović, G. A.; Miodragović, Z. M.; Radulović, M. Đ.; Novaković, S. B.; Kaluđerović, G. N.; Kozłowski, H. J. Inorg. Biochem. 2006, 100, 1568–1574. doi:10.1016/j.jinorgbio.2006.05.009
    Return to citation in text: [1]
  105. Sprague, J. M.; Land, A. H.; Ziegler, C. J. Am. Chem. Soc. 1946, 68, 2155–2159. doi:10.1021/ja01215a010
    Return to citation in text: [1]
  106. Hirata, Y.; Yanagisawa, I.; Ishii, Y.; Tsukamoto, S.; Ito, N.; Isamura, Y.; Takeda, M. Guanidinothiazole Compounds, Process for Preparation and Gastric Inhibiting Compositions Containing them. U.S. Patent 4,283,408, Aug 11, 1981.
    Return to citation in text: [1]
  107. Hasegawa, M. Heterocycles 1998, 47, 857–864. doi:10.3987/COM-97-S(N)89
    Return to citation in text: [1]
  108. Yevich, J. P.; New, J. S.; Smith, D. W.; Lobeck, W. G.; Catt, J. D.; Minielli, J. L.; Eison, M. S.; Taylor, D. P.; Riblet, L. A.; Temple, D. L., Jr. J. Med. Chem. 1986, 29, 359–369. doi:10.1021/jm00153a010
    Return to citation in text: [1]
  109. Nadkarni, D. V.; Hallissey, J. F. Org. Process Res. Dev. 2008, 12, 1142–1145. doi:10.1021/op800105j
    Return to citation in text: [1] [2]
  110. Walinsky, S. W.; Fox, D. E.; Lambert, J. F.; Sinay, T. G. Org. Process Res. Dev. 1999, 3, 126–130. doi:10.1021/op980210k
    Return to citation in text: [1]
  111. Huguet Clotet, J.; Puig Torres, S. Process for the Preparation of Ziprasidone. Eur. Patent 1975169, Oct 1, 2008.
    Return to citation in text: [1]
  112. Price, B. J.; Clitherow, J. W.; Bradshaw, J. W. Aminoalkylfuranderivate, Verfahren zu ihrer Herstellung und diese Verbindungen erhaltende Arzneimittel. Ger. Patent 2734070, Dec 29, 1983.
    Return to citation in text: [1]
  113. Vlaovic, D.; Milic, B. L.; Mackenzie, K. J. Chem. Res., Synop. 1989, 6, 156–157.
    Return to citation in text: [1]
  114. Gever, G.; O’Keefe, C. J. Process for the Preparation of Azomethines of 5-Nitro-2-formylfurane with Hydrazine Compounds. U.S. Patent 2,927,110, March 1, 1960.
    Return to citation in text: [1]
  115. Witczak, M.; Kwiecień, H. Synth. Commun. 2005, 35, 2223–2230. doi:10.1080/00397910500182747
    Return to citation in text: [1]
  116. Wang, Z. J. Synthetic Process for 2-Butyl-3-(hydroxy-3,5-diiodobenzoyl)-benzofuran. Chin. Patent 1,858,042, Nov 8, 2006.
    Return to citation in text: [1]
  117. Ha, H. R.; Stieger, B.; Grassi, G.; Altorfer, H. R.; Follath, F. Eur. J. Clin. Pharmacol. 2000, 55, 807–814. doi:10.1007/s002280050701
    Return to citation in text: [1]
  118. Vogel, V. G.; Costantino, J. P.; Wickerham, D. L.; Cronin, W. M.; Cecchini, R. S.; Atkins, J. N.; Bevers, T. B.; Fehrenbacher, L.; Pajon, E. R., Jr.; Wade, J. L., III; Robidoux, A.; Margolese, R. G.; James, J.; Lippman, S. M.; Runowicz, C. D.; Ganz, P. A.; Reis, S. E.; McCaskill-Stevens, W.; Ford, L. G.; Jordan, V. C.; Wolmark, N. JAMA, J. Am. Med. Assoc. 2006, 295, 2727–2741. doi:10.1001/jama.295.23.joc60074
    Return to citation in text: [1]
  119. Jones, C. D.; Jevnikar, M. G.; Pike, A. J.; Peters, M. K.; Black, L. J.; Thompson, A. R.; Falcone, J. F.; Clemens, J. A. J. Med. Chem. 1984, 27, 1057–1066. doi:10.1021/jm00374a021
    Return to citation in text: [1]
  120. Aikins, J. A.; Miller, R. S. Vinyl Sulfoxides and a Process for their Synthesis. WO Patent 96/40691, Dec 19, 1996.
    Return to citation in text: [1]
  121. Chakrabarti, J. K.; Hotten, T. M.; Tupper, D. E. 2-Methylthienobenzodiazepine. U.S. Patent 5,627,178, May 6, 1997.
    Return to citation in text: [1]
  122. Chakrabarti, J. K.; Hotten, T. M.; Tupper, D. E. 2-Methylthienobenzodiazepine. U.S. Patent 5,229,382, July 20, 1993.
    Return to citation in text: [1]
  123. Berglund, R. A. Intermediate Useful for the Asymmetric Synthesis of Duloxetine. U.S. Patent 5,491,243, Feb 12, 1996.
    Return to citation in text: [1]
  124. Eng, W.-S.; Burns, D. H.; Ponticello, G. S.; Selwick, H. G. Short Synthesis of 5,6-Dihydro-(S)-4-(ethylamino)-(S)-6-[C3H3]-4H-thieno[2,3-b]thiopyran-2-sulfonamide-7,7-dioxide and Related Non-Radioactive Compounds. U.S. Patent 5,441,722, Aug 15, 1995.
    Return to citation in text: [1]
  125. Blacklock, T. J.; Sohar, P.; Butcher, J. W.; Lamanec, T.; Grabowski, E. J. J. J. Org. Chem. 1993, 58, 1672–1679. doi:10.1021/jo00059a013
    Return to citation in text: [1]
  126. Wang, L.; Shen, J.; Tang, Y.; Chen, Y.; Wang, W.; Cai, Z.; Du, Z. Org. Process Res. Dev. 2007, 11, 487–489. doi:10.1021/op700025d
    Return to citation in text: [1]
  127. Lodewijk, E.; Khatri, H. N. 2-(2-Nitrovinyl)thiophene Reduction and Synthesis of Thieno[3,2-c]pyridine Derivatives. Eur. Patent 342,118, Nov 15, 1989.
    Return to citation in text: [1]
  128. Kikuchi, C.; Hiranuma, T.; Koyama, M. Bioorg. Med. Chem. Lett. 2002, 12, 2549–2552. doi:10.1016/S0960-894X(02)00485-7
    Return to citation in text: [1]
  129. Hanson, M. A.; Cherezov, V.; Griffith, M. T.; Roth, C. B.; Jaakola, V.-P.; Chien, E. Y. T.; Velasquez, J.; Kuhn, P.; Stevens, R. C. Structure 2008, 16, 897–905. doi:10.1016/j.str.2008.05.001
    Return to citation in text: [1]
  130. Tosi, G.; Zironi, F.; Caselli, E.; Forni, A.; Prati, F. Synthesis 2004, 1625–1628. doi:10.1055/s-2004-822395
    Return to citation in text: [1]
  131. Vest, R. D. 3,4-Dichloro-1,2,5-thiadiazole and its Preparation. U.S. Patent 3,115,497, Dec 24, 1963.
    Return to citation in text: [1]
  132. Xu, J.; Shen, Y.; Xiang, L.; Deng, Y. Zhongguo Yiyao Gongye Zazhi 2005, 36, 593–595.
    Return to citation in text: [1]
  133. Lima, L. M.; Barreira, E. J. Curr. Med. Chem. 2005, 12, 23–49.
    Return to citation in text: [1]
  134. Ramakrishnam, A.; Gobind, K.; Neeraj, K.; Dnyaneshwar, S. An Improved Process for Preparation of Leflunomides. WO Patent 2007/086076, Aug 2, 2007.
    Return to citation in text: [1]
  135. Ikuno, K.; Yoshida, S. Method for Producing 5-Methylisoxazole. Jap. Patent 2007/320855, Dec 13, 2007.
    Return to citation in text: [1]
  136. Reiter, L. A. J. Org. Chem. 1987, 52, 2714–2726. doi:10.1021/jo00389a015
    Return to citation in text: [1]
  137. Kennis, L. E. J.; Vanderberk, J. 3-Piperidinyl-substituted 1,2-Benzisoxazoles and 1,2-Benzisothiazoles. U.S. Patent 4,804,663, Feb 14, 1989.
    Return to citation in text: [1]
  138. Carey, J. S.; Laffan, D.; Thomson, C.; Williams, M. T. Org. Biomol. Chem. 2006, 4, 2337–2347. doi:10.1039/b602413k
    Return to citation in text: [1]
  139. Dugger, R. W.; Ragan, J. A.; Brown Ripin, D. H. Org. Process Res. Dev. 2005, 9, 253–258. doi:10.1021/op050021j
    Return to citation in text: [1]
  140. Francotte, E.; Lindner, W., Eds. Chirality in Drug Research: From Synthesis to Pharmacology; Methods and Principles in Medicinal Chemistry, Vol. 33; Wiley-VCH Verlag GmbH & Co. KgaA: Weinheim, Germany, 2006. doi:10.1002/3527609431
    Return to citation in text: [1]
  141. Ojima, I., Ed. Catalytic Asymmetric Synthesis, 3rd ed.; Wiley & Sons, Inc.: Hoboken, New Jersey, 2010. doi:10.1002/9780470584248
    Return to citation in text: [1]
  142. Baxendale, I. R.; Hayward, J. J.; Ley, S. V.; Tranmer, G. K. ChemMedChem 2007, 2, 768–788. doi:10.1002/cmdc.200700008
    Return to citation in text: [1]
Other Beilstein-Institut Open Science Activities